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Transcription is strictly regulated by numerous factors including transcription
coactivators. The p300 protein and its close paralogue CREB-binding protein
(CREBBP, aka CBP) are well-known transcriptional coactivators that have
intrinsic lysine acetyltransferase activity. The functions of p300/CBP largely rely
on their capabilities to bind to chromatin and to acetylate the histone substrates.
However, the molecular mechanisms underlying the regulation of these
processes are not fully understood.
Through combination of various biochemical, biophysical and molecular
approaches, we show that the ZZ-type zinc finger (ZZ) domain of p300 functions
as a histone reader that specifically binds the N-terminal tail of histone H3.
Crystal structure of p300 ZZ in complex with the H3 peptide reveals that the ZZ
domain adopts a negatively charged cavity to anchor Ala1 and Arg2 of H3. The
ZZ-H3 interaction is not sensitive to common post-translational modifications,
such as methylation or acetylation, on the H3 tail. Both in vitro and cell-based
assays reveal that p300 ZZ domain, together with bromodomain (BRD), is
important in recruiting p300 to chromatin. As a module adjacent to the histone
acetyltransferase (HAT) domain, ZZ domain is also required for efficient histone
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acetylation by HAT. The recognition of histone H3 by the ZZ domain selectively
promotes p300-dependent acetylation specifically on histone H3K27 and H3K18,
whereas the acetyllysine binding activity of BRD is required for acetylation of
virtually all lysine residues in H3 and H4 tails.
p300/CBP are frequently mutated or dysregulated in many human diseases
including cancer. We found that p300 is overexpressed in small cell lung cancer
(SCLC), the most aggressive subtype of lung cancer. By CRISPR/Cas9mediated gene manipulation, we found that p300 depletion impedes proliferation
of human and mouse SCLC cells whereas CBP depletion has little or no effect.
Depletion of p300 reduces the expression of critical oncogenes such as the MYC
family genes, indicating that p300 promotes SCLC cell growth by sustaining
oncogene expression.
In summary, we identified the ZZ domain of p300 as a novel histone H3
reader that is critical for the chromatin association and enzymatic activity of p300.
Recognition of H3 by ZZ domain is important to the functions of p300 in human
cancer.
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Chapter 1. Introduction

Copyright information:
Contents of Chapter 1.1-1.3 are based on my review article: Xue Y*, Wen H, Shi
X*. 2018. CBP/p300: intramolecular and intermolecular regulations. Front Biol.
13: 168-179. (*: Corresponding authors). I am the primary author of this review.
Permission to reuse the whole article for thesis was obtained from
www.copyright.com with license number: 4456690546571.

1.1 Transcriptional coactivators CBP/p300
Transcription is critical for deciphering the commands encrypted in DNA
for the completion of various important biological processes. Regulation of this
molecular event in eukaryotes is complex, but strictly controlled by a vast
network of regulatory factors. Two of these factors are cAMP response elementbinding protein (CREB)-binding protein (CREBBP, aka CBP or lysine
acetyltransferase 3A, KAT3A) and its close paralogue p300 (aka KAT3B) (1, 2).
CBP and p300 were initially identified as interacting proteins of CREB and
adenoviral protein early region 1A (E1A), respectively (3-7). Both proteins contain
intrinsic histone lysine acetyltransferase (HAT) activity (8, 9) and constitute the
KAT3 family of acetyltransferase in mammals. The encoding genes of CBP and
p300 in human genome are CREBBP and EP300, respectively.
Acetylation on histone lysine residues neutralizes positive charge on their
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side chain, weakens not only the interaction between histones and negatively
charged DNA but also that between neighboring nucleosomes, creating an open
chromatin structure that facilitates transcription (10). CBP and p300 have
promiscuous acetyltransferase activity. In vitro they are able to acetylate multiple
sites of histones H2A, H2B, H3 and H4 in the context of free histone (8) or
nucleosome (8, 9, 11). However, depletion (12-14) or inhibition (14, 15) of both
CBP and p300 in cells greatly reduces the global level of histone H3K18 and K27
acetylation without dramatically affecting acetylation at other sites, indicating that
they are mainly required for H3K18 and K27 acetylation in vivo. In response to
DNA damage, CBP/p300 acetylate H3K56 on free histones (16, 17), which is
required for chromatin reassembly after DNA repair (18). In addition to their
histone substrates, CBP/p300 can also acetylate many other proteins including
transcription factors (19). By interacting with hundreds of proteins, CBP and p300
work as scaffolds to assemble transcriptional activation complexes, or serve as
bridges linking the activator complexes to the RNA polymerase II (Pol II)
transcription machinery (20-22). Consistent with their roles in transcriptional
activation, CBP/p300 are mainly localized at regulatory DNA elements, especially
enhancers (23, 24). In fact, the genomic occupancy of CBP/p300 has been used
as a predictive marker for active enhancers (25).
CBP and p300 proteins are composed of multiple conserved domains,
which, from N- to C-terminus, include a nuclear receptor-interacting domain
(NRID), a transcriptional adapter zinc-binding (TAZ1) domain, a kinase-inducible
domain interacting (KIX) domain, a bromodomain (BRD), a combined Really
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Interesting New Gene (RING) domain and plant homeodomain (PHD), a HAT
domain that contains an autoinhibitory loop (AIL), a ZZ-type zinc finger (ZZ)
domain, another TAZ domain (TAZ2) and an interferon binding domain (IBiD)
(19). Of note, the TAZ1, RING/PHD and ZZ/TAZ2 domains each forms a
cysteine/histidine-rich region (CH), named as CH1, CH2 and CH3, respectively.
BRD, CH2, HAT domain and CH3 form the catalytic core of CBP/p300 (26).
Other domains and regions are linked to the catalytic core by long stretches of
unstructured regions (Figure 1A).
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Figure 1. The regulation of CBP/p300 acetyltransferase activity by AIL,
RING domain and BRD.
(A) Schematic representation of human CBP/p300 domain architecture. The
numbers of amino acid residues of CBP and p300 are labeled. (B) When the
HAT domain is in its inactive state, the hypoacetylated AIL occupies the
substrate-binding groove along with the RING domain packed in close proximity
4

to the HAT catalytic site. Upon autoacetylation of the AIL, it is displaced from the
catalytic site along with the RING domain, making the HAT domain accessible to
its substrates. (C) The BRD recognizes acetylated histones, preferentially
acetylated histone H4. Binding of acetylated histone tail by BRD facilitates the
recruitment of CBP/p300 to chromatin and also increases the access of HAT
domain to the histone substrate such as the H3 tail. Such an enhancement may
occur either in cis on the same nucleosome or in trans on adjacent nucleosomes.
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1.2 Intramolecular regulation mechanisms of CBP/p300
The functions of CBP/p300, especially their acetyltransferase activity and
chromatin association, are regulated both intramolecularly by their AIL, BRD, and
PHD-RING region and intermolecularly by their interacting partners and posttranslational modifications (PTM).
The AIL (aka autoregulatory loop or activation loop) is a lysine-rich loop
region adopting a disordered structure within the HAT domain (26, 27) (Figure
1A). It encompasses amino acid residues (AA) 1520-1581 and 1556-1618 of
human p300 and CBP, respectively. The AIL was discovered by the Philip Cole
laboratory when they studied how autoacetylation regulates the HAT activity of
p300 (28). Up to 17 lysine residues in the AIL and nearby regions of p300 can be
autoacetylated through an intermolecular mechanism (29, 30). When AIL is
hypoacetylated, it occupies the catalytic site of HAT domain with its lysine
residues interacting with the acidic residues in the substrate-binding groove of
HAT domain. This interaction prevents the positively-charged substrates such as
lysine-rich histone tails from entering the catalytic site, thus inhibiting the
acetyltransferase activity of p300 (30, 31). Acetylation on the AIL lysine residues
disrupts their binding to the substrate-binding groove of HAT domain (30),
displacing the AIL from the catalytic site. As a result, the catalytic site of HAT
domain becomes more accessible to its substrates and the acetyltransferase
activity is thus activated (Figure 1B). In addition to the modulation of HAT activity,
the AIL also plays a role in regulating CBP/p300 chromatin association. In an in
vitro system, autoacetylation of the AIL induces the dissociation of p300 from the
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preinitiation complex (PIC) containing GAL4-VP14 and Mediator at the
chromatin, which enhances both TFIID binding and transcription initiation (32).
The CH2 region, located between the BRD and HAT domains, is
comprised of a RING domain and a PHD. Crystal structure of the p300 catalytic
core encompassing the BRD, CH2 and HAT domains reveals that CH2 region
serves as a bridge to connect the BRD and HAT domains (27). The RING
domain is packed in close proximity to the HAT domain and restricts the access
of HAT active site to the AIL and other substrates (27, 30). Deletion of the RING
domain or the mutations in RING that impairs either its structural integrity or its
interaction with HAT enhances p300 autoacetylation (on K1499) and acetylation
of p53 substrate (on K382) (27, 30, 33), suggesting RING negatively regulates
the acetyltransferase activity of p300. Likewise, the RING domain of CBP shows
a similar regulatory role in both CBP autoacetylation and p53 acetylation (26).
However, in contrast to the enhanced autoacetylation and p53 acetylation,
acetylation on histone H3K9 and H3K14 is reduced by the deletion of p300 RING
domain (33), whereas in the case of CBP, RING deletion has no dramatic effect
on histone acetylation (26). These results suggest that the regulatory role of
RING in CBP/p300 acetyltransferase activity may be substrate-specific.
The PHD of p300 is discontinuous as it is interrupted by the RING domain
(27). Distinct from the mutations in RING, the mutations either within PHD or at
PHD-HAT interfaces do not strongly affect p300 autoacetylation or p53 substrate
acetylation (27). In addition, the PHD is not directly involved in the regulation of
p300/CBP chromatin binding, because unlike the canonical PHDs that function
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as readers recognizing modified or unmodified histones (34, 35), the CBP/p300
PHD does not recognize histones due to the lack of conserved residues critical
for histone binding (27, 36). To date, the actual function of the PHD in CBP/p300
remains unknown.
Acetylated histone lysine can be recognized by specific reader proteins,
which facilitates the recruitment or retention of transcription co-activators at
acetylated chromatin loci. BRD is the first discovered reader of histone
acetylation (Dhalluin et al., 1999). The BRD in CBP/p300 has histone- and
nucleosome-binding capability (Manning et al., 2001; Ragvin et al., 2004). It
recognizes multiple acetylated histone peptides in vitro, preferentially di- and triacetylated histone H4 and H2B (27, 36). Substitution of Asn1132 (N1132), a
conserved residue within the hydrophobic acetyllysine-binding pocket of p300
BRD, to alanine abolishes its binding to all acetylated histone peptides (27).
Furthermore, deletion of BRD prevents p300 from forming stable and direct
interaction with nucleosomes (Manning et al., 2001); and treatment of CBP30, a
small-molecule inhibitor targeting CBP/p300 BRD, in cells displaces CBP/p300
from chromatin (37, 38), suggesting that a functional BRD is required for p300chromatin association.
Although CBP/p300 BRD is not adjacent to the HAT domain, it is crucial to
CBP/p300-mediated histone acetylation. Deletion of BRD greatly impairs the
ability of p300 to acetylate histones in the contexts of nucleosome (39), native
chromatin (40) and recombinant chromatin (41) in vitro. In cells, the increase of
global histone H3K9ac and H3K14ac levels caused by ectopic p300 expression
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can be diminished by BRD deletion or mutations in its acetyllysine-binding pocket
(33). Interestingly, in contrast to its critical role in histone substrate acetylation,
loss of BRD does not significantly affect p300 autoacetylation or the acetylation
of non-histone substrate such as p53, indicating that BRD is not required for the
intrinsic acetyltransferase activity of p300 (27, 40, 41). Considering its nature as
a histone acetylation reader, BRD may function as a “hand” that grabs acetylated
histone tails, thus increasing the accessibility of nucleosome substrates to the
catalytic HAT domain of CBP/p300 (Figure 1C). This model is supported by the
recent finding that preexisting histone H4 acetylation in nucleosomes enhances
wild-type p300-catalyzed H3K18 acetylation while this enhancement is not
observed in p300 with BRD deletion or mutations (39). However, it remains
unclear whether the recognition of acetylated histone H4 by BRD facilitates
acetylation of the histone H3 within the same nucleosome (in cis model) or in the
adjacent nucleosomes (in trans model) (Figure 1C).
The critical role of CBP/p300 BRD in chromatin binding and histone
acetylation explains the requirement of BRD in CBP/p300-mediated transcription
enhancement (40) and gene activation (42). Consistently, CBP30 treatment in
cells, dramatically reduces H3K18ac and H3K27ac level at multiple CBP/p300
target loci and deactivates transcription of target genes in cells (38, 43). Thus,
the cooperation between BRD and HAT ensures efficient transcription activation
by p300/CBP on chromatin.
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1.3 Intermolecular regulation mechanisms of CBP/p300
In addition to the intramolecular regulation mechanisms described,
CBP/p300 are also subject to intermolecular regulation by numerous external
molecules, which is critical for the functions of CBP/p300 in response to various
cell signaling pathways (44, 45). Upon the perception of intra- or extracellular
signals, cells initiate a series of molecular events of signal transduction, leading
to activation of a group of genes and deactivation of others. CBP/p300 play
indispensable roles in activating gene expression in response to almost all
signaling pathways. CBP/p300 receive and execute commands from upstream
signals through signal-induced protein-protein interactions and PTMs, which
modulates the dynamics of chromatin association and HAT activity of CBP/p300.
To date, more than 400 proteins have been reported to interact with
CBP/p300 (19), including transcription factors, coactivators, mediators and basal
transcription machinery components. These protein-protein interactions allow
CBP/p300 to integrate the assembly of transcription activation complexes, to be
connected with the basal transcription machinery, and to gain access to a subset
of these proteins for acetylation (19, 46). CBP/p300 contain a number of domains
that interact with binding partners, including NRID, TAZ1, KIX, TAZ2, IBiD, and to
a less extent, BRD and HAT domains (46). Notably, a single protein may interact
with multiple domains or regions of CBP/p300 simultaneously.
As CBP/p300 do not contain specific DNA-binding domains, recruitment of
CBP/p300 to specific chromatin regions, such as enhancers or promoters, is
achieved by interacting with transcription factors that bind to specific DNA
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sequences. A well-studied example is CREB, a transcription factor that
recognizes the DNA sequence known as cAMP-response elements (CREs).
Following the activation of G protein-coupled receptors (GPCRs), accumulated
cAMP promotes the catalytic subunit of protein kinase A (PKA) to dissociate from
its regulatory domain, diffuse into nucleus, and phosphorylate the kinaseinducible domain (KID) of CREB (47). Phosphorylation of KID (at Serine 133)
greatly increases its binding to the KIX domain of CBP. The CREB-CBP
interaction mediated by KID-KIX binding thus recruits CBP to CREs, leading to
the activation of cAMP-responsive genes (7, 48). The hydrogen bond formed
between phosphorylated Ser133 of CREB KID and Tyr658 of CBP KIX domain
plays an indispensable role in the interaction between these two domains (49).
Upon interaction with KIX, the unstructured KID undergoes a coil-to-helix
transition, forming two helices, with one helix interacting with the hydrophobic
groove of KIX to stabilize KID-KIX interaction (49).
Intermolecular protein-protein interactions also directly regulate the HAT
activity of CBP/p300. P300 was originally discovered as one of the proteins that
bind E1A, an adenoviral oncoprotein (3, 4). Small E1A protein, the shorter
isoform of E1A, contains three conserved regions (CR1-3), with CR1 and CR2
interacting with CBP/p300 and retinoblastoma (RB) proteins, respectively (50).
Binding of small E1A to the TAZ2 domain of CBP/p300 inhibits their HAT activity
on histones in vitro, thus repressing CBP/p300-dependent transcription (51-53).
Infection of cells with adenovirus Type 5 (Ad5) dl1500 that expresses only small
E1A markedly reduces global H3K18 acetylation level, which mimics the

11

phenotype when both CBP and p300 are depleted (13). Interestingly, small E1A
can be acetylated at K239 by CBP/p300, implying that as a substrate of
CBP/p300, small E1A may inhibit HAT activity by directly competing with
histones for the catalytic site of CBP/p300 (54).
In contrast to small E1A that inhibits CBP/p300 HAT activity, Mastermind
like 1 (MAML1), another protein that binds to p300 TAZ2 domain, activates its
HAT activity both in vitro (55) and in vivo (56), probably through potentiating p300
autoacetylation (56). MAML1 also helps to recruit p300 to the genomic loci of
Notch pathway genes (57), suggesting that MAML1 regulates both HAT activity
and chromatin association of p300. Additionally, dimerization of transcription
factors that interact with p300 (IRF3, STAT1 etc.) can engage two p300
molecules, which increases the likelihood of p300 AIL autoacetylation in trans,
thus enhancing its HAT activity (30).
In addition to protein interactors, CBP also directly binds to RNAs (58).
Interestingly, CBP-bound RNAs arise from the chromatin regions with high CBP
occupancy and a large fraction of them are enhancer RNAs (eRNAs). eRNAs are
non-coding RNAs transcribed from enhancers (59). Those CBP-bound eRNAs
directly bind to AIL and displace it from the HAT catalytic site, thus stimulating
HAT activity in vitro. Consistently, depletion of a certain eRNA in cells greatly
reduces the H3K18 and H3K27 acetylation level at the same enhancer where
this eRNA is originated and its associated promoter without affecting CBP
occupancy (58). This study suggests that when CBP is recruited to active
enhancers where eRNAs are produced and locally enriched, these eRNAs can

12

bind to the AIL of CBP to stimulate its HAT activity, leading to a local increase of
CBP-dependent histone acetylation at the same enhancer and associated
promoters. This finding also indicates that in addition to AIL autoacetylation, cells
may employ multiple mechanisms to ensure AIL is displaced from the HAT active
site, safeguarding histone acetylation and gene activation.
While CBP/p300 catalyze lysine acetylation on histones and non-histone
proteins, they themselves are also subject to PTMs, such as phosphorylation,
methylation and SUMOylation, which in turn affects the functionality and
homeostasis of CBP/p300.
CBP/p300 can be phosphorylated at various sites. For example, AKT
phosphorylates p300 at S1834 (60), ERK1/2 phosphorylate p300 at S2279,
S2315 and S2366 (61), and mTORC1 phosphorylates p300 at S2271, S2279,
S2291 and S2315 (62). All these phosphorylation events stimulate HAT activity.
In contrast, PKC-catalyzed p300 phosphorylation at S89 inhibits the catalytic
activity of p300 (63). The mechanisms by which phosphorylation at the N- or Cterminal distal regions regulate the HAT domain that is located in the central
region of p300 have remained elusive. However, Wan et al. recently showed that
mTORC-catalyzed p300 phosphorylation in the C-terminal region abrogates the
interaction between p300 HAT and RING domain, thus releasing the HAT
catalytic site from the RING domain-mediated inhibition (62). This finding
indicates the existence of crosstalk between inter- and intramolecular regulation
mechanisms of CBP/p300. Phosphorylation can also regulate CBP/p300
homeostasis. For instance, phosphorylation of p300 S106 by ATM contributes to

13

p300 stabilization in response to double-strand breaks (DSBs) (64) while
MAPK/AKT-catalyzed p300 S1834 phosphorylation induces p300 degradation
during nucleotide excision repair (NER) (65).
In addition to phosphorylation, other PTMs also contribute to CBP/p300
regulation. Coactivator-associated arginine methyltransferase 1 (CARM1)
interacts with and methylates CBP/p300 at multiple arginine residues (66-68).
Methylation of arginine residues at different regions has distinct regulatory
outcomes. For example, methylation of the arginine residues within the KIX
domain of disrupts CBP/p300-CREB interaction, thus reducing the recruitment of
CBP/p300 to the chromatin of CREB target loci (67) whereas methylation of the
arginine residues located downstream of KIX increases the recruitment of CBP to
estrogen receptor (ER)-responsive target genes and enhances CBP HAT activity
(68, 69). Additionally, SUMOylation of CBP/p300 on the lysine residues upstream
of BRD negatively regulates CBP/p300-mediated transcription, probably through
the recruitment of transcriptional corepressor Daxx (70, 71).
A summary of both intramolecular and intermolecular mechanisms
regulating p300/CBP is depicted in Figure 2. In the future, a deeper
understanding of how all the regulatory regions coordinate with each other in the
context of the complete CBP/p300 proteins will be required.
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Figure 2. Summary of intramolecular and intermolecular mechanisms
regulating CBP/p300.
The mechanisms regulating CBP/p300 acetyltransferase activity (A) and
chromatin association (B) are shown. Lines with arrows indicate positive
regulation whereas blunt-ended lines indicate negative regulation. *: the negative
regulatory role of the RING domain in CBP/p300 acetyltransferase activity is only
observed on non-histone substrates.

15

1.4 Physiological roles of CBP/p300
CBP/p300 are essential for various cellular processes such as cell
proliferation, differentiation and apoptosis (45). They play critical roles in mammal
development, memory consolidation and pathogenesis.
Mice homozygous null for either CBP (Crebbp-/-) or p300 (Ep300-/-) are
embryonic lethal (72-74). Crebbp-/- mice die around embryonic day 10.5~12.5
(E10.5~E12.5) (72) while Ep300-/- die around E9.0~E11.5 (73). Embryos from
both mutants display severe defects in growth and neural tube closure (73). In
addition, Crebbp+/- Ep300+/- double heterozygotes are also embryonic lethal and
single heterozygotes show reduced viability and multiple developmental defects
(73, 75, 76). These studies indicate that CBP and p300 exert overlapping
functions and that there may be a significant dosage requirement for both genes
during embryonic development.
Heterozygous mutations/deletions of CREBBP or, less commonly, EP300,
cause Rubinstein–Taybi syndrome (RTS) (77, 78), a human genetic disorder
characterized by mental retardation, broad thumbs and toes, craniofacial defects
and cardiac abnormalities (79). Consistently, monoallelic loss (75, 76) or
truncation of Crebbp (80) in mice also causes phenotypes reminiscent of RTS.
In addition, both CBP (75) and p300 (81) are crucial for hematopoiesis.
However, they seem to play distinct roles in this process. CBP, but not p300, is
critical to hematopoietic stem cell self-renewal while p300 plays more important
roles in hematopoietic differentiation (82). Furthermore, CBP is also required for
long-term memory consolidation in mice brain (83-85). The expression of
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deactivated or truncated CBP in mice causes defects in long-term memory
formation and synaptic plasticity through a dominant-negative mechanism (86).
CBP/p300 are involved in a number of human cancers. Somatic mutations
of CREBBP and EP300 frequently occur in multiple types of malignancies (87),
such as colorectal cancer (88, 89), lung cancer (88, 90), breast cancer (88), skin
cancer (91) and lymphoma (92-94). Most of these mutations are missense
mutations clustering within HAT domain or its adjacent regions as well as
frameshifts and nonsense mutations resulting in protein truncations (Figure 3)
(92, 93, 95), implying that inactivation of CBP/p300 acetyltransferase activity may
contribute to tumorigenesis. In addition, CREBBP, and less commonly, EP300,
are targets of chromosome translocations. MLL-CREBBP (96, 97), MLL-EP300
(98), MOZ-CREBBP (99) and MOZ-EP300 (100) translocations have been
implicated in acute myeloid leukemia (AML) and myelodysplastic syndrome.
The precise roles of CBP/p300 in cancers are complicated. They function
as tumor suppressors in certain types of cancers, such as colon cancer (101,
102) and B-cell lymphoma (103). Recently, the elegant work from four labs
clearly demonstrate the function and mechanism of CBP in B-cell lymphoma
(103-106). Follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)
are the two most common types of non-Hodgkin lymphomas derived from
germinal center (GC) B cells. The mutation rates of CREEBP in DCBCL and FL
are around 30% and 60%, respectively (92, 93, 107). In comparison, EP300 is
less frequently mutated in FL and DLBCL. Although GC B cells-specific knockout
of Crebbp alone is not sufficient to drive oncogenic transformation in mice, it

17

cooperates with Bcl2 overexpression, an event that frequently co-occurs with
Crebbp mutations in human FL and DLBCL, to promote lymphomagenesis (104,
106), indicating Crebbp is a tumor suppressor gene. Mechanistically, CBP
directly binds to the promoter and enhancers of a large number of genes involved
in B cell signaling and GC exit (104) in GC B cells. Loss of CBP represses the
expression of these target genes by reducing the histone H3K27 acetylation level
at their enhancers (103, 104). As most CBP target genes are also occupied by
the BCL6-containing transcription repressor complex (103, 104), the function of
this repressor complex may become more dominant on these genes when CBP
is depleted, which contributes to the silencing of these genes and
lymphomagenesis (103). Interestingly, the timing of CBP mutation matters in
lymphoma because loss of Crebbp in early stages of lymphopoiesis is
advantageous for lymphoid transformation whereas Crebbp loss after lymphoid
fate commitment does not show an obvious phenotype (105).
CBP/p300 are also reported to play roles in promoting oncogenesis or
disease maintenance in other types of cancers. For example, high expression of
CBP/p300 was correlated with poor prognosis in prostate cancer (108),
hepatocellular carcinomas (109) and lung cancers (110, 111). In addition, p300 is
required for androgen receptor (AR) expression and prostate tumorigenesis in a
PTEN-deficient mouse model (112). CBP/p300 also work as the coactivators of
AR to support the androgen-induced gene expression in prostate cancer (113).
Consistently, small-molecule inhibitors targeting the CBP/p300 HAT domain
efficiently reduces prostate cancer cell viability and represses tumor growth (15,
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114). Furthermore, CBP/p300 also facilitate the induction and maintenance of
AML both in vitro and in vivo (115), which may partially be dependent on their
interaction with c-Myb (116, 117). The oncogenic roles of CBP/p300 in AML
suggest that they may be promising therapeutic targets (115, 118).
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Figure 3. Mutation diagrams of human CREBBP and EP300 genes based on
215 cancer genomic studies.
The mutation diagrams of human CREBBP (A) and EP300 (B) genes were
obtained from cBio Cancer Genomics Portal (http://cbioportal.org) (119, 120) on
4/27/2018. Mutation types and corresponding color codes are as follows:
Green: missense mutations. Black: truncating mutations (nonsense, nonstop,
frameshift deletion or insertion, splice site variant). Brown: in-frame deletion, inframe insertion. Purple: all other types of mutations.
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1.5 ZZ-type zinc finger (ZZ) domain
The ZZ domain is a small (~45 AA) motif with a cross-braced zinc finger
topology. It uses s cysteine residues and 2 histidine residues to coordinate 2 Zn2+
ions (121). This domain was named ZZ for its capacity to bind two Zn2+ ions
(122). The ZZ domain was originally identified in dystrophin, a cohesive protein
critical to muscle fiber integrity, and its related proteins (122). Dystrophin is a vital
subunit of the dystrophin-associated protein complex that connects the actin
cytoskeleton of muscle fibers to the surrounding extracellular matrix (123). The
ZZ domain of dystrophin is located within its C-terminal cysteine-rich domain and
is required for its interaction with the transmembrane adhesion receptor βdystroglycan (124), which is crucial to dystrophin function.
ZZ domain has been identified in approximately 20 human proteins with
various functions including chromatin modification, RNA processing, cytoskeletal
scaffolding, ubiquitin binding or conjugating, and autophagy (121). The
phylogenetic tree and sequence alignment of the ZZ domains from multiple
proteins are shown in Figure 4. The function of the ZZ domain has been poorly
studied. A few ZZ domains were reported to be involved in protein-protein
interaction. For example, p62 ZZ domain interacts with RIP1 in NF-κB pathway
(125) and the ZZ domains of the E3 ligase HERC2 (126) and CBP (127) bind
Small Ubiquitin-like Modifier 1 (SUMO1). However, a more comprehensive
understanding of ZZ domains’ functions is in need.
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Figure 4. Phylogenetic tree and sequence alignment of ZZ domains in
human proteins.
(A) Phylogenetic tree presentation of ZZ domains in human proteins. (B)
Sequence alignment of human ZZ domains. Identical residues are in white text
shaded in red. Conserved residues are in red text and framed by blue line.
Figure 4 is adapted from Mi W, Zhang Y, Lyu J, Wang X, Tong Q, Peng D, Xue
Y, Tencer AH, Wen H, Li W, Kutateladze TG and Shi X. 2018. The ZZ-type zinc
finger of ZZZ3 modulates the ATAC complex-mediated histone acetylation and
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gene activation. Nat Comm. 9:3759. Permission to reuse these figures for thesis
was obtained from www.copyright.com with license number 4456700921676.
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1.6 Small cell lung cancer (SCLC)
Lung cancer is divided into three main subtypes (Figure 5A): non-small
cell lung cancer (NSCLC), small cell lung cancer (SCLC) and lung carcinoid
tumor (http://www.cancer.org/cancer/lungcancer/index). SCLC, the most
aggressive subtype, accounts for 10~15% of all lung cancer cases and is tightly
associated with heavy smoking behavior in patients (128). This disease is
characterized by rapid tumor expansion, frequent relapse and early metastasis
(129). SCLC cells are small, poorly differentiated, and likely originated from
neuroendocrine cells within the pulmonary epithelium (130, 131).
SCLC is commonly divided into limited stage and extensive stage. Limited
stage SCLC is confined to a single radiation field in one side of the chest while
extensive stage SCLC has distant metastases (132). Approximately two-thirds of
SCLC patients are diagnosed with extensive stage (133). In general, limitedstage patients are treated concurrently with chemotherapy in combination with
radiation therapy, whereas extensive-stage patients are treated with
chemotherapy alone (134). Despite the initial good response to frontline
therapies in most SCLC patients, the disease will soon relapse with resistance to
second-line and subsequent therapies. Numerous clinical trials since the 1970s
have failed and there are still no approved targeted drugs for this disease. The 5year survival rate of SCLC patients remains lower than 7% (128, 134).
The mutation rate of SCLC is among the highest, which can be explained
by its link to tobacco exposure (135). Genomic studies have revealed multiple
recurrent genetic alterations in SCLC (Figure 5B, C). For example, loss-of-

24

function mutations in TP53 and RB1 are present in almost all SCLC samples (95,
136, 137). Amplified SOX2 (137) and MYC family genes (138, 139), activated
phosphatidylinositol 3 kinase (PI3K) pathway and inactivated NOTCH signaling
pathway are also common (95, 136, 140, 141).
In addition to the genetic alterations, dysregulated epigenetic mechanisms
also contribute to SCLC onset and progression. For example, Enhancer of zeste
homolog 2 (EZH2), a core subunit of the polycomb repressive complex 2 (PRC2)
and a histone H3K27-specific methyltransferase, is highly expressed in SCLC
compared to normal lung tissues and other cancer types (142-145). This might
be the result of E2 promoter binding factors (E2Fs) upregulation, which is caused
by the universal RB1 loss or frequent E2Fs amplification in SCLC (143).
Overexpressed EZH2 directly silences TGFBR2, the gene encoding transforming
growth factor-β (TGF-β) type II receptor (TβRII), by catalyzing histone H3K27
trimethylation at its promoter, which suppresses TGF-β pathway, enabling SCLC
cells to escape apoptosis (146). EZH2 also directly silences Schlafen family
member 11 (SLFN11), a gene critical to DNA damage response, to promote the
resistance to chemotherapy in SCLC (147). Inhibiting EZH2 with small molecules
such as EPZ reduces SCLC xenograft tumor growth (145) and prevents the
acquisition of chemoresistance in SCLC (147).
While anti-tumor genes are silenced, oncogenes such as MYC, MYCN,
NFIB, SOX2, NEUROD1 and ASCL1, are expressed at very high levels in SCLC
(148-153). Recently it has been reported that these highly-expressed oncogenes
are associated with large and clustered enhancer elements containing
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extraordinarily high level of H3K27ac (153, 154), namely super-enhancers (155).
Many factors involved in transcription activation, such as BET proteins, mediator
components and p300/CBP, are enriched at super-enhancers to maintain the
activation of those oncogenes (154). Inhibition of the BET family member BRD4
by JQ1 (156, 157) or the cyclin-dependent kinase CDK7 by THZ1 (153) in SCLC
suppresses the expression of super-enhancer-associated oncogenes and cell
growth.
EP300 and CREBBP are also frequently mutated in SCLC (90, 95, 136,
137, 158) with mutation frequencies of 13% and 15%, respectively (136).
Alterations in EP300 and CREBBP are mutually exclusive (95). Except for the
inactivating translocations, mutations of EP300 and CREBBP are clustered within
the HAT domain and its adjacent regions (95, 136). However, only a few of
mutations in HAT domain have been confirmed to reduce HAT activity (95),
whereas the functional consequences of most mutations are still elusive. SCLC
patient survival analysis has not revealed any significant differences between
individuals with and without EP300/CREBBP mutations (136). Interestingly, high
p300/CBP expression levels have been reported to be associated with poor
overall survival for resected SCLC patients (111). Direct evidence clearly
revealing the roles of p300/CBP in SCLC initiation and progression is still lacking.
The pathogenesis of SCLC is a complex, multi-step process.
Understanding the genetic and epigenetic basis of SCLC will contribute to the
development of novel therapies. In the future, more multidisciplinary and
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comprehensive studies will be required for translating these biological findings
into clinical practice.
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Figure 5. Genetic alterations in small cell lung cancer.
(A) The classification of lung cancers. (B) The somatic mutations of candidate
genes in SCLC tumor samples. Tumor samples are arranged from left to right.
Alterations of SCLC candidate genes are annotated for each sample according to
the color panel below the image. The somatic mutation frequencies for each
candidate gene are plotted on the right panel. Mutation rates and type of basepair substitution are displayed in the top and bottom panel, respectively.
Significant candidate genes are highlighted in bold (*corrected q-values < 0.05,
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†P < 0.05, ‡P < 0.01). The respective level of significance is displayed as a
heatmap on the right panel. Genes that are also mutated in murine SCLC tumors
are denoted with a § symbol. Mutated cancer census genes of therapeutic
relevance are denoted with a + symbol. (C) Somatic copy number alterations
determined for 142 human SCLC tumors by single nucleotide polymorphism
(SNP) arrays. Significant amplifications (red) and deletions (blue) were
determined for the chromosomal regions and are plotted as q-values
(significance < 0.05).
Figure 5B and 5C are adapted from George, J., J. S. Lim, S. J. Jang, Y. Cun, L.
Ozretic, G. Kong, F. Leenders, X. Lu, L. Fernandez-Cuesta, G. Bosco, C. Muller,
I. Dahmen, N. S. Jahchan, K. S. Park, D. Yang, A. N. Karnezis, D. Vaka, A.
Torres, M. S. Wang, J. O. Korbel, R. Menon, S. M. Chun, D. Kim, M. Wilkerson,
N. Hayes, D. Engelmann, B. Putzer, M. Bos, S. Michels, I. Vlasic, D. Seidel, B.
Pinther, P. Schaub, C. Becker, J. Altmuller, J. Yokota, T. Kohno, R. Iwakawa, K.
Tsuta, M. Noguchi, T. Muley, H. Hoffmann, P. A. Schnabel, I. Petersen, Y. Chen,
A. Soltermann, V. Tischler, C. M. Choi, Y. H. Kim, P. P. Massion, Y. Zou, D.
Jovanovic, M. Kontic, G. M. Wright, P. A. Russell, B. Solomon, I. Koch, M.
Lindner, L. A. Muscarella, A. la Torre, J. K. Field, M. Jakopovic, J. Knezevic, E.
Castanos-Velez, L. Roz, U. Pastorino, O. T. Brustugun, M. Lund-Iversen, E.
Thunnissen, J. Kohler, M. Schuler, J. Botling, M. Sandelin, M. SanchezCespedes, H. B. Salvesen, V. Achter, U. Lang, M. Bogus, P. M. Schneider, T.
Zander, S. Ansen, M. Hallek, J. Wolf, M. Vingron, Y. Yatabe, W. D. Travis, P.
Nurnberg, C. Reinhardt, S. Perner, L. Heukamp, R. Buttner, S. A. Haas, E.
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Brambilla, M. Peifer, J. Sage, and R. K. Thomas. 2015. Comprehensive genomic
profiles of small cell lung cancer. Nature 524: 47-53. Permission to reuse these
figures for thesis was obtained from www.copyright.com with license number:
4324930807544.

30

Chapter 2. Materials and Methods

2.1 Plasmids and molecular cloning.
The coding DNA sequences (CDS) encoding human full-length p300
protein and various p300 fragments were amplified from pcDNA3.1-p300 vector
(#23252) purchased from Addgene. The CDS of full-length p300 and p300 BDRING-PHD-HAT-ZZ-TAZ2 region (BRPHZ, amino acids 1035-1830) and cloned
into pENTR3C vector and subsequently cloned into p3FLAG and pCDH-3FLAG
destination vectors using Gateway techniques (Invitrogen). The CDS encoding
the human p300 BD-RING-PHD-HAT-ZZ region (BRPHZ, amino acids 10351720) and ZZ domain (amino acids 1650-1720) were cloned into the pGEX-6P-1
vector (GE Healthcare). Point mutations and deletions were generated using a
site-directed mutagenesis kit (Stratagene) and verified by Sanger sequencing.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
guide RNAs (gRNAs) were designed by the online CRISPR design tool of Feng
Zhang’s lab (http://crispr.mit.edu/) for human and mouse EP300/CREBBP genes.
Two gRNAs targeting the 5’ region of each gene’s CDS and one non-target
control gRNA were used in this study. The oligos encoding those gRNAs were
annealed and then cloned into lentiCRISPRv2 puro vector (#98290, Figure 6)
purchased from Addgene.
The detailed information of all the vectors and oligos are included in Table
1 and 2, respectively.
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Figure 6. The map of LentiCRISPR v2 Puro vector.
The vector was linearized by BsmI digestion. The DNAs encoding gRNAs were
inserted between two BsmI restriction sites. This figure is made using DNASTAR
SeqBuilder Pro.
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Name
pGEX-p300-ZZ
pGEX-p300-ZZ D1664A
pGEX-p300-ZZ F1666A
pGEX-p300-ZZ Y1668A
pGEX-p300-ZZ N1671A
pGEX-p300-ZZ R1680C
pGEX-p300-ZZ W1681A
pGEX-p300-ZZ D1688K
pGEX-p300-ZZ D1690A
pGEX-p300-BRPHZ
pGEX-p300-BRPHZ ∆AIL
pGEX-p300-BRPH
pGEX-p300-BRPHZ N1132A
pGEX-p300-BRPHZ D1399A
pGEX-p300-BRPHZ N1671A
pGEX-p300-BRPHZ D1690A
pGEX-p300-BRPHZ N1132A
D1690A
pENTR3C-p300-BRPHZT
pENTR3C-p300-BRPHZT ∆ZZ
pENTR3C-p300-BRPHZT ∆BRD
pENTR3C-p300-BRPHZT
∆ZZ&BRD
pENTR3C-p300-BRPHZT ∆AIL
pENTR3C-p300-BRPHZT N1132A
pENTR3C-p300-BRPHZT D1399A
pENTR3C-p300-BRPHZT N1671A
pENTR3C-p300-BRPHZT D1690A
pENTR3C-p300-BRPHZT N1132A
D1690A
pENTR3C-p300FL
pENTR3C-p300FL N1671A
pENTR3C-p300FL D1690A

Region cloned

Application

p300 AA1650-1720
p300 AA1650-1720
p300 AA1650-1720
p300 AA1650-1720
p300 AA1650-1720
p300 AA1650-1720
p300 AA1650-1720
p300 AA1650-1720
p300 AA1650-1720
p300 AA1035-1720
p300 AA1035-1720
(1520-1581 del)
p300 AA1035-1669
p300 AA1035-1720
p300 AA1035-1720
p300 AA1035-1720
p300 AA1035-1720

Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression

p300 AA1035-1720

Prokaryotic expression

p300 AA1035-1830
p300 AA1035-1830
(1664-1705 del)
p300 AA1162-1830
p300 AA1162-1830
(1664-1705 del)
p300 AA1035-1830
(1520-1581 del)
p300 AA1035-1830
p300 AA1035-1830
p300 AA1035-1830
p300 AA1035-1830

Gateway cloning

p300 AA1035-1830

Gateway cloning

p300 full-length CDS
p300 full-length CDS
p300 full-length CDS

Gateway cloning
Gateway cloning
Gateway cloning

Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression
Prokaryotic expression

Gateway cloning
Gateway cloning
Gateway cloning
Gateway cloning
Gateway cloning
Gateway cloning
Gateway cloning
Gateway cloning

Table 1. Plasmids used in this study.
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Name
pCDH-3FLAG-p300-BRPHZT
pCDH-3FLAG-p300-BRPHZT ∆ZZ
pCDH-3FLAG-p300-BRPHZT ∆BRD
pCDH-3FLAG-p300-BRPHZT
∆ZZ&BRD
pCDH-3FLAG-p300-BRPHZT ∆AIL

Region cloned
p300 AA1035-1830
p300 AA1035-1830
(1664-1705 del)
p300 AA1162-1830
p300 AA1162-1830
(1664-1705 del)
p300 AA1035-1830
(1520-1581 del)
p300 AA1035-1830
p300 AA1035-1830
p300 AA1035-1830
p300 AA1035-1830

pCDH-3FLAG-p300-BRPHZT N1132A
pCDH-3FLAG-p300-BRPHZT D1399A
pCDH-3FLAG-p300-BRPHZT N1671A
pCDH-3FLAG-p300-BRPHZT D1690A
pCDH-3FLAG-p300-BRPHZT N1132A
p300 AA1035-1830
D1690A
pCDH-3FLAG-p300FL
p300 full-length CDS
pCDH-3FLAG-p300FL N1671A
p300 full-length CDS
pCDH-3FLAG-p300FL D1690A
p300 full-length CDS
p3FLAG-p300FL
p300 full-length CDS
p3FLAG-p300FL N1671A
p300 full-length CDS
p3FLAG-p300FL D1690A
p300 full-length CDS
Human CBP gRNA5-LentiCRISPRv2
NA
Human CBP gRNA6-LentiCRISPRv2
NA
Human p300 gRNA1-LentiCRISPRv2 NA
Human p300 gRNA6-LentiCRISPRv2 NA
Mouse CBP gRNA3-LentiCRISPRv2
NA
Mouse CBP gRNA6-LentiCRISPRv2
NA
Mouse p300 gRNA2-LentiCRISPRv2
NA
Mouse p300 gRNA5-LentiCRISPRv2
NA

Application
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Lentiviral expression
Transfection
Transfection
Transfection
Gene depletion
Gene depletion
Gene depletion
Gene depletion
Gene depletion
Gene depletion
Gene depletion
Gene depletion

Table 1 (continue). Plasmids used in this study.
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2.2 Primers
The sequences and usages of all primers/oligos used in this study are
described in Table 2.
Oligo name
p300-fl-KpnI-F
p300-fl-XhoI-R
p300-BRD-EcoRI-F
p300-PHD-EcoRI-F
p300-HAT-XhoI-R
p300-ZZ-XhoI-R
p300-TAZ2-XhoI-R
p300-dAIL-F
p300-dAIL-R
p300-dZZ-F
p300-dZZ-R
p300-ZZ-D1664A-F
p300-ZZ-D1664A-R
p300-ZZ-F1666A-F
p300-ZZ-F1666A-R
p300-ZZ-Y1668A-F
p300-ZZ-Y1668A-R
p300-ZZ-N1671A-F
p300-ZZ-N1671A-R
p300-ZZ-R1680C-F
p300-ZZ-R1680C-R
p300-ZZ-W1681A-F
p300-ZZ-W1681A-R
p300-ZZ-D1688K-F
p300-ZZ-D1688K-R
p300-ZZ-D1690A-F
p300-ZZ-D1690A-R
p300-HAT-D1399A-F
p300-HAT-D1399A-R
p300-BRD-N1132A-F
p300-BRD-N1132A-R

Sequence (5'-3')
GGGGTACCATGGCCGAGAATGTG
GCGCCTCGAGCTAGTGTATGTCTAG
CGGAATTCACCCAGTCATCTCC
CGGAATTCTACTGTTGTGGCAGA
GCGCCTCGAGTTAGGTGTAGACAAAGCG
GCGCCTCGAGTTACTGCTGGTTGTTGC
GCGCCTCGAGTTACCTGCGAAGCATTTG
GAAAGCATTAAGGAACAGAAACTATATGCC
GGCATATAGTTTCTGTTCCTTAATGCTTTC
CACACGCAGAGCCAGGAGAAACTAGGCCTT
AAGGCCTAGTTTCTCCTGGCTCTGCGTGTG
CACACGCAGAGCCAGGCCCGCTTTGTCTACACC
GGTGTAGACAAAGCGGGCCTGGCTCTGCGTGTG
CAGAGCCAGGACCGCGCTGTCTACACCTGCAAT
ATTGCAGGTGTAGACAGCGCGGTCCTGGCTCTG
CAGGACCGCTTTGTCGCCACCTGCAATGAATGC
GCATTCATTGCAGGTGGCGACAAAGCGGTCCTG
TTTGTCTACACCTGCGCTGAATGCAAGCACCAT
ATGGTGCTTGCATTCAGCGCAGGTGTAGACAAA
CACCATGTGGAGACATGCTGGCACTGTACTGTC
GACAGTACAGTGCCAGCATGTCTCCACATGGTG
CATGTGGAGACACGCGCGCACTGTACTGTCTGT
ACAGACAGTACAGTGCGCGCGTGTCTCCACATG
TGTACTGTCTGTGAGAAGTATGACTTGTGTATC
GATACACAAGTCATACTTCTCACAGACAGTACA
GTCTGTGAGGATTATGCCTTGTGTATCACCTGC
GCAGGTGATACACAAGGCATAATCCTCACAGAC
TACATATCTTACCTCGCTAGTGTTCATTTCTTC
GAAGAAATGAACACTAGCGAGGTAAGATATGTA
AATGCCTGGTTATATGCCCGGAAAACATCACGG
CCGTGATGTTTTCCGGGCATATAACCAGGCATT

Application
Cloning
Cloning
Cloning
Cloning
Cloning
Cloning
Cloning
Deletion
Deletion
Deletion
Deletion
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis
Mutagenesis

Table 2. Oligos used in this study.
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Oligo name
NBPF1-46k-F
NBPF1-46k-R
NOTCH2NL-d4k-F
NOTCH2NL-d4k-R
DMPK-1k-F
DMPK-1k-R
PDE4DIP-U10k-F
PDE4DIP-U10k-R
INSM1-D8k-F
INSM1-D8k-R
ASCL1-P-F
ASCL1-P-R
ASCL1-D5k-F
ASCL1-D5k-R
Myc-ChIP-P1k-F
Myc-ChIP-P1k-R
Myc-ChIP-P0.1k-F
Myc-ChIP-P0.1k-R
mMyc-RTq-F
mMyc-RTq-R
mMycl-RTq-F
mMycl-RTq-R
mMycn-RTq-F
mMycn-RTq-R
mAscl1-RTq-F
mAscl1-RTq-R
mNfib-RTq-F
mNfib-RTq-R
MYC-RTq-F
MYC-RTq-R
MYCL1-RTq-F
MYCL1-RTq-R
MYCN-RTq-F
MYCN-RTq-R
ASCL1-RTq-F
ASCL1-RTq-R
NEUROD1-RTq-F
NEUROD1-RTq-R

Sequence (5'-3')
TCAAGAGCCCAGCCAACAC
CAGCCCTACAGAAGTGCCTTTT
AGCCCTTCGGGACACATG
GGGCTTCCACTCTTCCAAAGT
CACCCAGAAGAACCCAAAGTTG
GGAGAACCAGCTTTGCAGACA
TCTCGTGCCATCCACTCTATCTC
GCCTGGATGTGCTGGACAA
CCCAGTTGTTGCCCCAGTAA
TGGTGCCCAAGCCATCA
GCACGCACTGCAACAACAA
CTCCCGCTCCTTGCAAACT
GAGTTTGAGACTAGCCTGGGAAAG
CCAGCACCTTCAGCTAATTTTTG
CAGCCCGAGACTGTTGCA
TTTCAGAAGAGACAAATCCCCTTT
CCCGGGTTCCCAAAGC
CCAGACCCTCGCATTATAAAGG
GTCTTTCCCTACCCGCTCAAC
GTGGAATCGGACGAGGTACAG
GGCAACAGCAACTGCAAAAG
CAGGCGTTCTGGTCGGTTAG
TGCCCGCGAGAAGCTAGA
CGTGGCCGTGCTGTAGTTT
TCCTGTCGCCCACCATCT
AGAACCCGCCATAGAGTTCAAG
CCCGTGCTGTGTCTTATCCA
AGGCAGTCGATCCTCCTAATCTT
CGTCTCCACACATCAGCACAA
CACTGTCCAACTTGACCCTCTTG
GGAGCGGACATGGACTACGA
GCCGTGGAGCGGTAGAAAT
AATTGAACACGCTCGGACTTG
AATGTGCAAAGTGGCAGTGACT
GAGCAACTGGGACCTGAGTCA
CCCACTGCTTTTGCACACAA
AAGGTGGTGCCTTGCTATTCTAA
CCAAGCGCAGAGTCTCGATT

Application
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
ChIP-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR
RT-qPCR

Table 2 (continue). Oligos used in this study.
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Oligo name
CBP-gRNA5-5'
CBP-gRNA5-3'
CBP-gRNA6-5'
CBP-gRNA6-3'
EP300-gRNA1-5'
EP300-gRNA1-3'
EP300-gRNA6-5'
EP300-gRNA6-3'
mCBP-gRNA3-5'
mCBP-gRNA3-3'
mCBP-gRNA6-5'
mCBP-gRNA6-3'
mEP300-gRNA2-5'
mEP300-gRNA2-3'
mEP300-gRNA5-5'
mEP300-gRNA5-3'
NT-gRNA2-5'
NT-gRNA2-3'

Sequence (5'-3')

CACCGCGCGGGACTGAACACCGCAC
AAACGTGCGGTGTTCAGTCCCGCGC
CACCGGCAGCCGAACAGTGCTAACA
AAACTGTTAGCACTGTTCGGCTGCC
CACCGGTTCAATTGGAGCAGGCCGA
AAACTCGGCCTGCTCCAATTGAACC
CACCGGAATTGGGACTAACCAATGG
AAACCCATTGGTTAGTCCCAATTCC
CACCGGGCCTTCTCAATAGTAACTC
AAACGAGTTACTATTGAGAAGGCCC
CACCGAGCGGCTCTAGCATCAACCC
AAACGGGTTGATGCTAGAGCCGCTC
CACCGATGAACGGTTCCATTGGAGC
AAACGCTCCAATGGAACCGTTCATC
CACCGGGCCACCGACTCCCATGTTG
AAACCAACATGGGAGTCGGTGGCCC

CACCGGGATACTTCTTCGAACGTTT
AAACAAACGTTCGAAGAAGTATCCC

Application
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA
CRISPR gRNA

Table 2 (continue). Oligos used in this study.
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2.3 Antibodies
The information of all the primary and secondary antibodies used in this
study is included in Table 3.

Antibody

Vendor
Abcam
Abcam
Abcam
Active Motif
Active Motif
Abcam
Millipore
Santa Cruz
Sigma
Santa Cruz
Santa Cruz
Sigma

Catalog #
Ab1791
Ab176799
Ab32129
61251
39755
Ab4729
06-598
Sc-459
F1804
Sc-585
Sc-369
T8328

Application
WB, ChIP
WB
WB
WB
WB, ChIP
WB, ChIP
WB
WB
WB, ChIP
WB
WB
WB

IRDye® 800CW Goat
anti-Rabbit IgG

LI-COR

926-32211

WB (secondary)

IRDye® 680LT Goat antiMouse IgG

LI-COR

926-68020

WB (secondary)

Peroxidase-conjugated
Donkey anti-Mouse IgG

Jackson Immuno
Research

715-035-150

WB (secondary)

Peroxidase-conjugated
Donkey anti-Rabbit IgG

Jackson Immuno
Research

711-035-152

WB (secondary)

Anti-H3
Anti-H3K4ac
Anti-H3K9ac
Anti-H3K9ac
Anti-H3K18ac
Anti-H3K27ac
Anti-acetyl-Histone H4
Anti-GST
Anti-FLAG
Anti-p300
Anti-CBP
Anti-β-Tubulin

Table 3. Antibodies used in this study.
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2.4 Cell lines
The information of all cell lines used was described in Table 4. They were
mycoplasma-negative and tested for authentication by short tandem repeat
(STR) profiling by the MDACC Characterized Cell Line Core.
Cell line
HEK293T
HBEC
A549
H1299
H1048
H1836
H209
H2171
H524
H69
H82
ID43
Kp1
Kp3

Species
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Human
Mouse
Mouse
Mouse

Cancer type
Kidney cancer
Lung epithelial control cell
NSCLC
NSCLC
SCLC
SCLC
SCLC
SCLC
SCLC
SCLC
SCLC
Pre-SCLC
SCLC
SCLC

Medium
DMEM*
KSFM**
RPMI
RPMI
HITES***
HITES
RPMI****
HITES
RPMI
RPMI
RPMI
RPMI
RPMI
RPMI

Source
ATCC
Dr. John Heymach
Dr. John Heymach
Dr. John Heymach
Dr. Lauren Byers
Dr. Lauren Byers
Dr. Lauren Byers
Dr. Lauren Byers
Dr. Lauren Byers
Dr. Lauren Byers
Dr. Lauren Byers
Dr. Kwon-Sik Park
Dr. Julien Sage
Dr. Julien Sage

Kp3+GFP+Luc Mouse

SCLC

RPMI

Dr. Julien Sage

Kp12
259-2

SCLC
SCLC

RPMI
RPMI

Dr. Julien Sage
Dr. Julien Sage

Mouse
Mouse

Table 4. Cell lines used in this study.
*DMEM: Dulbecco's Modified Eagle Medium (Cellgro) supplemented with 10%
fetal bovine serum (FBS) (Sigma). **KSFM: Keratinocyte serum-free medium.
***HITES: DMEM/F12 Medium (Cellgro) supplemented with ITS mixture (Lonza,
containing 0.005 mg/ml Insulin, 0.01 mg/ml Transferrin and 30nM Sodium
selenite), 10 nM Hydrocortisone (Sigma), 10 nM β-estradiol (Sigma), 4.5 mM Lglutamine (Cellgro) and 5% FBS (Sigma). **** RPMI: Roswell Park Memorial
Institute 1640 medium (Cellgro) supplemented with 10% FBS (Sigma).
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2.5 Protein expression and purification
The CDS of p300BRPHZ or p300ZZ cloned in the pGEX-6P-1 vector were
expressed in BL21 Rosetta 2 cells. Protein production was induced with 0.2 mM
IPTG and cultured overnight at 16 °C in Luria broth (LB) medium supplemented
with 0.05 mM ZnCl2. The glutathione S-transferase (GST)-tagged proteins were
purified on glutathione Sepharose 4B beads (Amersham) in binding buffer (50
mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% NP-40, 1 mM PMSF plus protease
inhibitors (Roche)) at 4 °C for 4 hours and eluted by 100 mM Tris pH 8.0
containing 15 mg/mL Reduced Glutathione (Sigma) at 4 °C for overnight. Eluted
proteins were supplemented with 25% glycerol before frozen at -80 °C. All
proteins harboring mutations or deletions were expressed and purified as WT
proteins.

2.6 Peptide microarray and pull-down assays
Biotinylated histone peptides bearing different modifications were
synthesized at CPC, LLC. For peptide microarray, biotinylated histone peptides
were printed in triplicate onto a streptavidin-coated slide (PolyAn) using a
VersArray Compact Microarrayer (Bio-Rad). After a short blocking with biotin
(Sigma), the slides were incubated with the glutathione S-transferase (GST)tagged p300 ZZ domain in binding buffer (50 mM Tris-HCl, pH 7.5, 250 mM
NaCl, 0.1% NP-40, 1 mM PMSF, 20% FBS) overnight at 4 °C with gentle shake.
After washed with the same buffer, the slides were probed with an anti-GST
primary antibody and then a fluorescein-conjugated secondary antibody and
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visualized using a GenePix 4000 scanner (Molecular Devices). For peptide pulldown, 1 μg of each biotinylated histone peptide was incubated with 1-2 μg of
GST-fused p300 ZZ domain in binding buffer (50 mM Tris-HCl pH 7.5, 250 mM
NaCl, 0.1% NP-40, 1 mM PMSF) for overnight with rotation at 4 °C. Streptavidin
beads (Amersham) were added to the mixture, and the mixture was incubated for
1 hour with rotation at 4 °C. The beads were then washed three times and the
bound proteins were analyzed using SDS–PAGE and Western blotting.

2.7 Calf thymus histone pull-down assay
2 µg GST-tagged p300ZZ domain were incubated with 10 µg of calf thymus
total histones (Worthington) in binding buffer (50 mM Tris-HCl pH 7.5, 1M NaCl,
1% NP-40) at 4 °C for overnight with rotation. Glutathione Sepharose 4B beads
(Amersham) were added to the solution and incubate for 1 h. The beads were
then washed six times using binding buffer and the bound histones were
detected using SDS–PAGE and Western blotting.

2.8 In vitro histone acetyltransferase (HAT) assays
For HAT assays on recombinant nucleosomes containing full-length histone
H3.1, purified wild type or mutated p300BRPHZ (300 nM) was incubated with
recombinant mononucleosome (100 nM) in HAT reaction buffer (50 mM Tris
pH 8.0, 0.1 mM EDTA, 10% glycerol, 1 mM PMSF and 1mM DTT) in a total
volume of 50 µL. After pre-warming at 37 °C for 5 minutes, reactions were
initiated with the addition of acetyl-CoA (Sigma) to a final concentration of 0.1
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mM and incubated for 10~80 minutes at 37 °C. For assays comparing the HAT
activities on recombinant nucleosomes containing full-length histone H3.1 and Nterminally truncated H3.1, wild type p300BRPHZ fragment (50 nM) and
monobucleosome (500 nM) were incubated under the same condition for 1 to 6
hours. Reactions were quenched by flash-freezing in liquid nitrogen and then
analyzed by SDS-PAGE and Western blot analysis. Western blot results were
quantified by LI-COR Odyssey and normalized to a common standard sample.

2.9 Western blot
Cells were lysed in RIPA buffer (50 mM TrisHCl pH7.4, 150 mM NaCl, 2
mM EDTA, 1% NP-40, 0.1% SDS) and sonicated for 20s at 15% intensity.
Generally, 15~30 µg protein lysate was loaded into various percentages of SDSpolyacrylamide gels for electrophoresis in PAGE running buffer (25 mM Tris, 192
mM glycine, 0.1% SDS, pH8.3). Then proteins were transferred to 0.2 or 0.45 μm
PVDF membrane in transfer buffer (25 mM Tris, 192 mM glycine, 0.1% SDS,
20% methanol). The membranes were blocked by TBST buffer (150 mM NaCl,
10 mM Tris pH8.0, 0.1% Tween20) supplemented with 5% non-fat milk for 1 hour
at room temperature and then blotted with primary antibodies overnight at 4°C on
an orbital shaker. After three times of wash by TBST, membranes were
incubated with secondary antibodies for 1 hour at room temperature and washed
again by TBST for 3 times. The membranes were then either used for filmdeveloping in darkroom after incubating with ECL Western Blotting Detection
Reagent (GE Healthcare) for 5 min or directly scanned by LI-COR Odyssey.
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2.10 Transfection and lentiviral infection
Transient transfection was performed using X-tremeGENE DNA
transfection reagent (Roche). 48 h after transfection, cells were collected for
Western blot analysis. For packaging lentivirus, 293T cells were co-transfected
with pMD2.G, pPAX2 (Addgene) and pCDH (or LentiCRISPRv2) constructs using
X-tremeGENE DNA transfection reagent (Roche). For infections, cells were
incubated with viral supernatants in the presence of 8 mg/ml polybrene; after 48
hours, the infected cells were selected with blasticidin (10 µg/ml) or puromycin (2
µg/ml) for 4-6 days before experiments.

2.11 Salt fractionation
The method of salt fractionation was modified from Tjian lab protocol (159). In
short, cells were swollen with hypotonic buffer (10 mM HEPES pH 7.9, 1.5 mM
MgCl2, 10mM KCl) and lysed by gentle disruption to isolate nuclei. The nuclei
were incubated with wash buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl2, 0.2mM
EDTA, 25% glycerol) containing 75 mM NaCl for 30 min at 4 °C and then pelleted
and the supernatant fraction was collected. The nuclei were then similarly
washed by wash buffer containing 150mM, 300mM and 600mM NaCl and the
supernatant fraction of each step was collected (Figure 7). After the final wash
step, the pellet was resuspended and sonicated before collection. All fractions
collected were analyzed by SDS–PAGE and Western blotting.
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Figure 7. The workflow for salt fractionation assay.
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2.12 Chromatin immunoprecipitation (ChIP) and ChIP-seq
ChIP analysis was performed as described in our previous papers (160,
161). In brief, cells were cross-linked with 1% formaldehyde for 10 min and
stopped by adding 125 mM glycine. The isolated nuclei were resuspended in
nuclei lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) and sonicated
using a Bioruptor Sonicator (Diagenode) for two cycles. The samples were
immunoprecipitated with 2–4 μg of the appropriate antibodies overnight at 4 °C.
Protein A/G beads (Millipore) were added and incubated for 1 hour, and the
immunoprecipitates were washed twice, each with low-salt (20 mM Tris pH 8.0,
150 mM NaCl, 2 mM EDTA, 1% Triton X-100 and 0.1% SDS), high-salt (20 mM
Tris pH 8.0, 500 mM NaCl, 2 mM EDTA, 1% Triton X-100 and 0.1% SDS) and
LiCl buffer (20 mM Tris pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% NP-40 and 1%
SDS). DNA was eluted from the beads using elution buffer (50 mM NaHCO3, 1%
SDS) and then reverse-crosslinked, purified using PCR purification kit (Qiagen).
The purified DNA was analyzed by quantitative real-time PCR on the ABI 7500FAST System using the Power SYBR Green PCR Master Mix (Applied
Biosystems). The primer sequences for ChIP-qPCR are listed in Table 2.
For ChIP-seq, the purified DNA was sequenced using the Illumina Solexa
Hiseq 3000. The raw reads were mapped to human reference genome NCBI 37
(hg19) or the Drosophila melanogaster genome (dm3) by bowtie v1.1.0, allowing
up to 1 mismatch. Only uniquely mapped reads were retained for peak calling.
But before that, we use spike-in normalization for sample size correction as
previously described (162). For simplicity, the reads were downsampled to keep
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same spike-in reads count in different samples. Then the ChIP-seq peaks were
called by MACS v1.4.2 with a cutoff of p ≤1e−8, and clonal reads were
automatically removed by MACS. The ChIP-seq reads density was determined
by deepTools v2.3.4, and then the average binding profile and heatmap were
visualized using R v3.2.3.

2.13 ChIP-western blot
The ChIP-western blot (ChIP-WB) assay was largely similar to ChIP
assay. Briefly, cells were cross-linked with 1% formaldehyde for 10 min and
stopped by adding 125 mM glycine. The isolated nuclei were resuspended in
nuclei lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) and sonicated
using a Bioruptor Sonicator (Diagenode). Anti-FLAG M2-conjugated agarose
beads (Sigma) were incubated with sonicated lysates overnight at 4 °C. The
beads were washed twice, each with low-salt (20 mM Tris pH 8.0, 150 mM NaCl,
2 mM EDTA, 1% Triton X-100 and 0.1% SDS), high-salt (20 mM Tris pH 8.0, 500
mM NaCl, 2 mM EDTA, 1% Triton X-100 and 0.1% SDS) and LiCl buffer (20 mM
Tris pH 8.0, 250 mM LiCl, 1 mM EDTA, 1% NP-40 and 1% SDS), and the bound
proteins were analyzed by SDS-PAGE and Western blot.

2.14 RNA extraction, reverse transcription (RT), and RT-qPCR
Total RNA was extracted using an RNeasy plus kit (QIAGEN) and
reverse-transcribed using an iScrip reverse transcription kit (Bio-Rad).
Quantitative real-time PCR (qPCR) analyses were performed using Power SYBR
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Green PCR Master Mix and the ABI 7500-FAST Sequence Detection System
(Applied Biosystems). Gene expressions were calculated following normalization
to GADPH levels using the comparative Ct (cycle threshold) method. The primer
sequences for RT-qPCR are listed in Table 2.

2.15 Cell proliferation assay
Cells were seeded into a 96-well plate for 200~500 cells in 100 µL
medium per well in triplicate for each time point and their proliferation was
measured every one or two days depending on the growth rate of those cells.
There is a tight linear relationship between cell number and the concentration of
ATP measured in cell lysate. The bioluminescence-based reagents such as
CellTiter-Glo (Promega) can detect ATP, which provides a sensitive readout of
cell proliferation. For proliferation measurement, directly add 25 µL CellTiter-Glo
into each well and gently rock the plate for 2 minutes on an orbit shaker to induce
cell lysis. Then incubate the plate at room temperature for 10 minutes to stabilize
luminescent signal before reading it using Fluostar Omega plate reader.

2.16 Statistical analyses
Data were presented as mean ± s.e.m. unless stated otherwise. Statistical
significance was calculated by two-tailed unpaired t-test on two experimental
conditions with P < 0.05 considered statistically significant unless stated
otherwise. Statistical significance levels are denoted as follows: *P < 0.05; **P <
0.01. No statistical methods were used to predetermine sample size.
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Figure 8. The expression, purification and peptide microarray analysis of
p300 ZZ domain.
(A) Schematic representation of full-length p300 protein and the prokaryotic
expression vector of p300 ZZ domain. (B) SDS-PAGE analysis of GST-tagged
p300 ZZ domain before and after purification. The arrow points out the band for
GST-p300ZZ. IPTG: isopropyl β-D-1-thiogalactopyranoside. FT: flow-through. (C)
The histone peptide microarray probed with GST-tagged p300 ZZ domain.
Histone peptides were printed in triplicate with their names labeled on the left or
right.
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Chapter 3. The ZZ Domain of p300 Recognizes Histone H3 to Regulate
Chromatin Association and Histone Acetylation

Copyright information:
Contents of Chapter 3.1-3.5 are based on Zhang Y*, Xue Y*, Shi J, Ahn JW, Mi
W, Ali M, Wang X, Klein BJ, Wen H, Li W, Shi X and Kutateladze TG. 2018. The
ZZ domain of p300 mediates specificity of the adjacent HAT domain for histone
H3. Nat Struct Mol Biol. 25: 841–849. (*: Co-first authors). According to this
journal, authors retain the rights “to reproduce the contribution in whole or in part
in any printed volume (book or thesis) of which they are the author(s)”.

3.1 p300 ZZ domain is a reader for histone H3
To determine the function of p300 ZZ domain in histone binding, we
performed histone peptide microarray using the GST-tagged p300 ZZ domain.
GST-p300 ZZ showed a molecular weight ~32 kDa on SDS-PAGE (Figure 8A,
8B). On the histone peptide microarray, p300 ZZ bound to the unmodified H31-21
peptide and the H31-21 peptides containing mo-, di-, or tri-methylation on H3K4 or
H3K9, or symmetric (me2S) or asymmetric dimethylation (me2A) on H3R2 or
H3R17 (Figure 8C), suggesting that the ZZ domain is able to recognize H3 Nterminal tail independent of methylation on these residues.
To determine whether p300 ZZ domain specifically binds to histone H3 but
not other histones, we performed calf thymus histone pull-down assays using
GST-tagged p300 ZZ domain (Figure 9A). A known histone H3 reader, RBP2
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PHD1 domain (163), was used as a positive control. The GST protein was used
as a negative control. Western blots using specific histone antibodies revealed
that similar to RBP2 PHD1, p300 ZZ specifically pulled down H3, but not other
histones. Under the same condition, GST alone did not bind to any histone.
These results demonstrate that p300 ZZ domain is a histone H3-specific reader.
To identify the minimal region of H3 tail required for p300 ZZ binding, we
performed histone peptide pull-down using various fragments of histone H3
(Figure 9B). Consistent with the microarray data, p300 ZZ domain bound strongly
to the H31-22 peptide. The H31-8 peptide retained sufficient binding to p300 ZZ.
However, deletion of the first 4 amino acids from the N-terminus of H3 abolished
its binding to p300 ZZ. As expected, other H3 regions did not bind to p300 ZZ.
A number of residues on the histone H3 tail can be post-translationally
modified, more frequently with methylation and acetylation. To determine
whether methylation or acetylation on histone H3 affects p300 ZZ binding, we
performed histone peptide pull-down using histone peptides bearing methylation
or acetylation on various residues (Figure 10A). Consistent with the microarray
data, methylation or acetylation did not affect the binding of p300 ZZ domain to
the H3 tail. Furthermore, p300 ZZ did not bind to other regions of histone H3 or
H4, regardless of PTMs. Tryptophan fluorescence measurements revealed a Kd
value of 8.8 μM of p300 ZZ domain for unmodified H31-12 peptide, and 7.7 μM or
7.6 μM for the H3K4me3 or H3K4ac peptide, respectively (Figure 10B). All
together, these results demonstrate that the ZZ domain of p300 is a H3-specific
reader that is insensitive to histone modifications.
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Figure 9. The ZZ domain of p300 binds to histone H3 tail.
(A) Calf thymus histone pull-down assays of p300 ZZ domain. RBP2 PHD1 or
GST was used as a positive or negative control, respectively. (B) Peptide pulldown assays of p300 ZZ domain using the indicated histone H3 peptides.
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Figure 10. Recognition of H3 by p300 ZZ domain is not sensitive to
methylation or acetylation on H3.
(A) Peptide pull-down assays of the p300 ZZ domain with the indicated histone
peptides. (B) Binding affinities of p300 ZZ domain for the indicated histone
peptides measured by tryptophan fluorescence. The experiments were carried
out in triplicate for H3 and H3K4ac and in duplicate for methylated H3 by Yi
Zhang from the Kutateladze lab at University of Colorado.
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3.2 The structural basis of H3 recognition by p300 ZZ domain
Through collaboration with Dr. Tatiana Kutateladze’s lab at University of
Colorado School of Medicine, we determined the crystal structure of the p300
ZZ-H3 complex at 2.0 Å resolution. The complex structure was obtained using a
chimeric construct containing residues 1-6 of H3 linked to residues 1663-1713 of
p300. The structure showed that two H3-ZZ fusion proteins form complexes in
which the H3 region of one molecule is bound to the ZZ domain of another
molecule (Figure 11A). The p300 ZZ domain adopts a cross-brace topology
stabilized by two zinc-binding clusters, a couple of twisted two- and threestranded anti-parallel -sheets, and a short -helix (Figure 11B). The histone
residues pair with the first -strand (residues 1665-1669 of ZZ), creating the third
anti-parallel -stand and make extensive intermolecular contacts with the domain
(Figure 11B). Characteristic -sheet interactions are observed between the
backbone amides of Ala1, Thr3 and Gln5 of H3 and T1669, V1667 and R1665 of
the ZZ domain. Ala1 occupies a highly negatively charged binding site where the
NH3+ group of Ala1 is anchored through the hydrogen bonds with T1669 and
N1671 and a salt bridge with D1690 (Figure 11C, D). The guanidinium moiety of
Arg2 is restrained via a salt bridge with the carboxyl group of D1688 and
hydrogen bonds with the backbone carbonyl oxygen of E1687, whereas the
backbone amide of Arg2 is involved in direct and water-mediated hydrogen
bonding contacts with D1688. The side chain of Lys4 lays in a groove formed by
the aromatic ring of F1666 and the side chain of D1664, the negatively charged
carboxylic group of which forms a salt bridge with the -amino group of Lys4
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(Figure 11B, E). The formation of the salt bridge most likely accounts for the
indifference of p300 ZZ domain towards PTMs on H3K4, which would augment
cation- and hydrophobic interactions with F1666 but diminish the electrostatic
contact with D1664. The side chain of Gln5 is hydrogen bonded to the
guanidinium group of R1665 (Figure 11E).
This structural mechanism for the recognition of H3 distinguishes p300 ZZ
domain from all currently known histone H3 readers. For example, BHC80 PHD
finger, a H3 reader domain specifically recognizing K4-unmodified H3 tail (164),
also forms a negatively charged cavity to bind the Ala1 of H3 (Figure 11F).
However, this binding cavity is located on the opposite side of this domain as
compared with p300 ZZ (Figure 11C). In addition, unlike ZZ, BHC80 PHD
contains another site with negative charge to accommodate unmodified Lys4
(Figure 11F). Methylation on Lys4 disrupts its binding to this negatively charged
site of BHC80 PHD (164), but does not affect its interaction with p300 ZZ domain
because ZZ does not have this Lys4-accomadating site (Figure 11C). Therefore,
the molecular basis of ZZ-H3 interaction indicates that the ZZ domain represents
a novel family of histone readers.
Substitution of N1671, D1688 or D1690, the ZZ domain residues that are
responsible for binding Ala1 and Arg2 of H3, with an alanine or lysine, abolished
the ZZ-H3 interaction in peptide pull-down or calf thymus histone pull-down
assays (Figure 12A, B). Further, mutation of D1664, F1666 or Y1668 also
substantially reduced the binding, pointing to the essential role of the Lys4
coordination (Figure 12A, B).
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Figure 11. Structure of the p300 ZZ-H3 complex.
(A) The crystal structure of the linked H3-ZZ construct. (B) A ribbon diagram of
the p300 ZZ domain (light blue) in complex with histone H3 tail (residues 1-6)
(orange). (C) Electrostatic surface potential of p300 ZZ domain is colored blue
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(positive charge) and red (negative charge) with the bound histone H3 tail shown
in stick (green). (D) Zoom-in view of the histone H3 Ala1 binding site. (E) Zoomin view of the histone H3 Lys4 binding site. (F) The electrostatic surface potential
plot of the PHD finger of BHC80 recognizing the N-terminal sequence of histone
H3 (PDB: 2PUY) (164).
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Figure 12. Key residues required for ZZ-H3 binding.
(A) Peptide pull-down assays using wild type and mutated p300 ZZ domain. (B)
Calf thymus histone pull-down assays of the wild type p300 ZZ domain and the
indicated mutants.
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3.3 Recognition of H3 by the ZZ domain is required for p300-chromatin
association
Our in vitro data reveal that p300 ZZ domain specifically recognizes the
histone H3 tail. However, whether the ZZ-H3 interaction is important to the
functions of p300 in cells is unknown.
First, we asked the question whether the H3 recognition by ZZ is required
for p300-chromatin association. To address this question, we attempted to
determine the chromatin occupancy of the full-length wild-type (WT) p300 or ZZmutants in cultured cells. We cloned the full-length coding DNA sequences
(CDS) of EP300 gene into either lentiviral vector (pCDH) or retrovirial vector
(pBABE), and delivered the expressing vectors into H1299 cell line through viral
infection. Unfortunately, the stable cells thus established failed to express fulllength p300, likely due to the failure of the viruses in packaging the extra-large
CDS (7.2 kb) of p300.
To overcome this difficulty, we decided to use the p300 core fragment
(p300BRPHZT) that contains the BRD, RING, PHD, HAT, ZZ and TAZ2 domains
(Figure 13A) in our experimental system. The p300BRPHZT fragment cloned in the
pCDH-3XFLAG vector can be successfully introduced and stably expressed in
H1299 cells at a reasonable expression level. Therefore, using this p300BRPHZT
core fragment, we deleted the individual BRD, ZZ, AIL or BRD+ZZ to evaluate
the importance of these domains to chromatin binding of the p300 core fragment
in cells (Figure 13A).
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We performed salt fractionation assay in the cells stably expressing WT
p300BRPHZT fragment or its counterparts with individual domain deleted (Figure
13B). The more tightly a protein binds to chromatin, the higher salt concentration
is needed to wash it off from chromatin. WT p300BRPHZT bound strongly to
chromatin in cells, as wash buffer containing 0.6 M salt was needed to
completely wash it off from chromatin. In contrast, ZZ- or BRD-deleted fragments
bound more weakly to chromatin, as 0.3 M salt can wash them off from
chromatin. The BRD of p300 is known to bind acetylated histones, preferentially
acetylated H4 (27). It has been reported that BRD is required for p300 to form
stable interaction with chromatin (165). The reduced chromatin binding as a
result of BRD deletion in our salt fractionation assays is consistent with the
published data. Importantly, simultaneous deletion of both BRD and ZZ domain
caused a more profound decrease in chromatin binding than single deletions,
implying an additive effect. As expected, deletion of AIL did not affect chromatin
binding (Figure 13B).
Next, we performed chromatin immunoprecipitation (ChIP) using FLAG
M2 antibody followed by western blotting (ChIP-WB) of histone H3 to evaluate
chromatin association of the p300BRPHZT core fragment and the domain-deletion
mutants (Figure 13C). All FLAG-tagged p300 fragments were expressed at a
similar level, while the amount of histone H3 pulled down by the ZZ- or BRDdeletion mutants was much less than that of the WT p300BRPHZT, indicating that
loss of either domain reduces chromatin binding. Deletion of both domains led to
a further reduction whereas AIL deletion had little effect. All together, these
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results suggest that both ZZ and BRD are required for p300-chromatin
association.
To further determine the importance of the H3-binding activity of the ZZ
domain in p300-chromatin association, we introduced histone-binding deficient
point mutations (N1671A and D1690A, named as ZZmu1 and ZZmu2) into the
p300BRPHZT fragment (Figure 14A). A BRD point mutant, N1132A (named as
BRDmu), that fails to bind histone acetylation (27) was also tested. In addition,
we also constructed p300 fragment carrying D1690A and N1132A double
mutations (named as ZZmu+BRDmu).
Both salt fractionation and ChIP-Western assays revealed that mutation of
either domain reduced p300BRPHZT binding to chromatin and mutations of both
showed a more severe defect (Figure 14B, C), suggesting that the H3-binding
activity of the ZZ domain and the histone acetylation binding activity of BRD are
both required for chromatin association of p300 in cells.
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Figure 13. Both ZZ domain and BRD are required by p300 for chromatin
association.
(A) Schematic representation of full-length p300 protein and the p300 fragments
stably expressed in H1299 cells. (B) Salt fractionation of H1299 cells stably
expressing wild type or deletion-mutated FLAG-p300BRPHZT. The workflow for salt
fractionation assay is shown in Figure 7. (C) ChIP-WB analysis of wild type or
deletion-mutated FLAG-p300BRPHZT in H1299 stable cells.
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Figure 14. Both the H3-recognition ability of ZZ domain and the acetyllysine
binding activity of BRD are required by p300 for chromatin association.
(A) Schematic representation of full-length p300 protein and the p300 fragments
stably expressed in H1299 cells. (B) Salt fractionation of H1299 cells stably
expressing wild type or mutated FLAG-p300BRPHZT. The workflow for salt
fractionation assay is shown in Figure 7. (C) ChIP-WB analysis of wild type or
mutated FLAG-p300BRPHZT in H1299 stable cells.
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3.4 Recognition of H3 by the ZZ domain facilitates the acetylation of H3K18
and H3K27 by the HAT domain
Both BRD and the ZZ domain of p300 are adjacent to the catalytic HAT
domain. As we discussed in Chapter 1.2, recognition of acetylated histone H4 by
BRD increases the accessibility of nucleosome substrates to CBP/p300 HAT
domain, thus contributing to histone acetylation (39). So we speculated that ZZ
may regulate the enzymatic activity of HAT through a similar mechanism.
To test this hypothesis, we purified recombinant GST-tagged p300BRPHZ
fragment (encompassing BRD, RING, PHD, HAT and ZZ domains) and the same
fragment bearing various deletions/mutations (Figure 15A) and compared their
enzymatic activity on nucleosomes by in vitro HAT assays. These
deletions/mutations include ZZ domain deletion, AIL deletion, HAT catalytic dead
mutation D1399A (HATmu) (166), ZZ domain mutations N1671A or D1690A
(named as ZZmu1 or ZZmu2, respectively), BRD mutation N1132A (BRDmu),
D1690A and N1132A double mutations (ZZmu+BRDmu). All the mutations or
deletions did not affect the protein stability during purification.
Next we used these fragments as enzymes and recombinant
mononucleosomes (without pre-existing modifications) as substrate for in vitro
HAT assays. Equal molar amount of each fragment was used in the assays for
easy comparison (Figure 15B). Samples were collected at different time points:
0, 10, 20, 40, 60 and 80 min after reaction, and immunoblotted using specific
antibodies against H3K4ac, H3K9ac, H3K18ac, and H3K27ac. Total H3 was also
blotted as a loading control. The fluorescence intensity of each band was
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measured using Odyssey system. To compare signals from different gels, we
used pre-modified nucleosomes as a standard to run on each SDS-PAGE gel.
All values of fluorescence intensity across different gels were compared to the
common standard sample. All quantifications were based on three biological
replicates.
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Figure 15. The p300 fragments used in in vitro HAT assays.
(A) Schematic representation of p300 fragments used in in vitro HAT assays. (B)
Western blot analysis showing equal amount of p300 fragments used in the HAT
assays.
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As shown in Figure 16, histone acetylation signals gradually increased
during the time course, indicating the accumulation of products of the HAT
reaction. All four lysine residues tested, H3K27, H3K18, H3K9 and H3K4, can be
acetylated by the WT p300BRPHZ enzyme in vitro. Interestingly, deletion of ZZ
domain greatly reduced acetylation on H3K27 and H3K18 (Figure 16A, B) but not
on H3K9 and H3K4 (Figure 16C, D), suggesting that the ZZ domain is required
for efficient acetylation specifically on H3K27 and K18.
It has been previously reported that deletion of AIL can release the active
site creating a constitutively active HAT (28). Consistent with this, we found
deletion of AIL dramatically accelerated the acetylation at all lysine residues at
early time points such as 10, 20 and 40 min (Figure 16A-D). At 80 min, the
histone acetylation levels were comparable between reactions with WT and AILdeleted enzymes, implying that all substrates were fully acetylated at the last
time point. This is in agreement with a previously proposed model that the
hypoacetylated AIL contacts a negatively charged patch on the HAT domain
surface blocking the active site, whereas acetylation of AIL by HAT releases the
inhibitory loop, thus freeing the active site (28, 31). As a negative control, HAT
domain mutation D1399A abolished the acetylation of all sites tested.
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Figure 16. Deletion of ZZ domain specifically attenuated the acetylation of
H3K27 and H3K18.
H3K27ac (A), H3K18ac (B), H3K9ac (C), H3K4ac (D) and H3 (E) western blot
analysis of in vitro HAT assays using WT p300BRPHZ or its counterpart harboring
either ZZ deletion, AIL deletion or loss-of-catalytic activity HAT mutation
(D1399A), and the reconstituted mononucleosome. Quantification of the HAT
activity on each lysine was based on the fluorescence signal from three biological
replicates. A common standard sample is used for normalization in each
replicate.
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To further determine whether the regulatory role of ZZ on the HAT activity
of p300 is dependent on its H3-binding capability, we carried out the same in
vitro HAT assays to compare WT and ZZ-mutated p300BRPHZ fragment (ZZmu1 or
ZZmu2) (Figure 17). BRDmu and ZZmu+BRDmu were also included as controls.
Similar to deletion of ZZ, ZZ point mutations exhibited a much lower HAT activity
on H3K27 and H3K18 (Figure 17A, B), whereas acetylation of H3K9 and H3K4
were not reduced compared to the WT p300 fragment (Figure 17C, D). Different
from ZZ mutations that specific attenuated H3K18 and H3K27 acetylation, BRD
mutation led to a substantial decrease in acetylation of all lysine residues tested
(Figure 17A-D). Furthermore, double mutations of both ZZ and BRD totally
abolished the acetylation of all tested residues (Figure 17A-D). Together, these
results suggest that the acetyllysine binding function of BRD is necessary for the
overall catalytic activity of p300BRPHZ on histones, whereas recognition of H3 by
ZZ domain is specifically required for p300BRPHZ to acetylate H3K18 and H3K27.
Mutations simultaneously disrupting the functions of both domains may
completely disable p300’s access to nucleosomes, abolishing acetylation of all
histone substrates.
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Figure 17. H3 binding by ZZ domain facilitates p300 HAT activity on H3K18
and H3K27.
H3K27ac (A), H3K18ac (B), H3K9ac (C), H3K4ac (D) and H3 (E) western blot
analysis of in vitro HAT assays using WT or mutated p300BRPHZ and the
reconstituted mononucleosome. Quantification of the HAT activity on each lysine
was based on the fluorescence signal from three biological replicates. A common
standard sample is used for normalization in each replicate.
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Because the first two residues of H3 (Ala1-Arg2) are critical to the ZZ-H3
interaction, we speculated that the very N-terminal residues of H3 are also
required for the acetylation of H3K18 and H3K27 by p300 HAT. To test this
hypothesis, we carried out in vitro HAT assays of the WT p300BRPHZ fragment
using recombinant mononucleosomes containing full-length H3 (rNUC_H3_FL)
or H3 with the first two amino acid residues deleted (rNUC_H3_∆N). We found
that the removal of Ala1-Arg2 of histone H3 dramatically decreased acetylation of
H3K27 and H3K18 by p300 HAT (Figure 18A-B), likely due to the reduced ZZ-H3
interaction. However, since each nucleosome contains two H3 subunits, this
experiment cannot distinguish whether the recognition of H3 by p300 ZZ
facilitates the acetylation of K27 and K18 on the same H3 subunit (in cis) or on
the other H3 subunit in the same or adjacent nucleosomes (in trans). To clarify
this mechanism, we performed in vitro HAT assays using histone peptides as
substrates. We incubated the WT p300BRPHZ with the H31-33 peptide or the same
H3 peptide with the first two amino acids deleted (H33-33). Similar to the results of
the HAT assays on mononucleosomes, p300BRPHZ catalyzed H3K18ac and
H3K27ac more efficiently on H31-33 than on H33-33 (Figure 18C), supporting the in
cis model (but not excluding the in trans model).
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Figure 18. The first two residues of H3 are required for the acetylation of
H3K18 and H3K27.
(A) In vitro HAT assays using WT p300BRPHZ and the reconstituted
mononucleosome carrying either intact H3.1 (rNUC_H3_FL) or N-terminally
truncated H3.1 (rNUC_H3_∆N, Ala1 and Arg2 of both H3.1 are deleted). (B)
Quantification of the HAT activity on H3K18 and H3K27 based on the
fluorescence signal in (A) from three biological replicates. The 1 hr sample of
rNUC_H3_FL is used for normalization. (C) In vitro HAT assays using WT
p300BRPHZ and biotinylated H3 peptides.
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The in vitro HAT assays demonstrate that recognition of H3 by the ZZ
domain is required for the HAT domain of p300 to acetylate histone on H3K18
and H3K27. Next we asked whether this recognition has the same regulatory role
in cells. To address this question, we utilized the H1299 stable cells systems
established in Chapter 3.3 and evaluated global histone acetylation levels of
these H1299 cells by Western bot analysis. First, we compared various H3 and
H4 acetylation levels in the cells stably expressing WT FLAG-p300BRPHZT, ZZ,
BRD, or AIL deletion mutants as well as ZZ and BRD double deletion mutants
(Figure 19A). The Western blotting band intensities were quantified using
Odyssey and normalized by total H3 or H4 values. Heatmaps were generated
using the mean values of fold changes relative to the vector controls from three
biological replicates (Figure 19B). Compared with the control cells infected with
an empty vector, WT p300BRPHZT-expressing cells showed higher levels of global
H3K4ac, H3K18ac, H3K27ac and H4 tetra-acetylation (5~8-fold) and a
moderately higher H3K9ac level (~2-fold) (Figure 19A, B). Compared with the
WT p300BRPHZT-expressing cells, BRD deletion markedly reduced the acetylation
levels on all sites tested. In contrast, deletion of the ZZ domain specifically
decreased H3K18ac and H3K27ac levels, whereas the levels of H3K4ac,
H3K9ac or H4ac remained largely unchanged. Deletion of both ZZ and BRD
further reduced acetylation on H3K18 and H3K27 to an undetectable level
(Figure 19A, B). These results suggest that both BRD and the ZZ domain are
required for maintaining H3K18 and H3K27 acetylation in cells. Unlike the in vitro
HAT assays results, deletion of AIL did not dramatically change the acetylation
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levels of any site in cells (Figure 19A, B). One possible explanation is that the AIL
region of the ectopic p300BRPHZT fragment is hyperacetylated and stretching out
from the HAT active site, thus having a minimal inhibitory effect.
The results above demonstrate that while BRD is required for acetylating
all lysine residues, the ZZ domain is specifically required by p300 in acetylating
H3K18 and H3K27 in cells. Next, we sought to determine whether the importance
of ZZ and BRD in histone acetylation is dependent on their histone-binding
capabilities. In this regard, we compared the global histone acetylation levels of
H1299 cells stably expressing WT FLAG-p300BRPHZT and those expressing
FLAG-p300BRPHZT bearing point mutations in ZZ, BRD or both domains. Similar to
their respective deletion mutants, the BRD mutant failed to acetylate almost all
histone H3 and H4 lysine residues tested, and the two ZZ point mutations were
specifically defective in acetylating H3K18 and H3K27 (Figure 19C, D). Mutations
in both domains led to a more severe drop in H3K18ac and H3K27ac levels
compared to the ZZ or BRD single domain mutations (Figure 19C, D).
Furthermore, in a transient expression system expressing full-length p300
in 293T cells, introducing the loss-of-function mutations into the ZZ domain also
attenuated the full-length p300 in acetylating H3K18 and H3K27 (Figure 20A, B).
Together, these findings reveal that recognition of H3 by the ZZ domain plays a
critical role in facilitating p300-mediated H3K18 and H3K27 acetylation in cells
whereas the binding of acetylated histone by BRD is required for the acetylation
of all lysine residues on H3 and H4.
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Figure 19. H3 recognition by ZZ domain is critical to p300-mediated H3K18
and H3K27 acetylation in cells.
(A) Western blot analysis of histone acetylation levels in whole cell extract of
H1299 cells stably expressing wild type or deletion-mutated FLAG-p300BRPHZT.
(B) Heatmap of quantification of the indicated histone acetylation levels from
three biological replicates as in (A). Total H3 or H4 was used for normalization.
(C) Western blot analysis of histone acetylation levels in whole cell extract of
H1299 cells stably expressing wild type FLAG-p300BRPHZT or the indicated
mutants. (D) Heatmap of quantification of the indicated histone acetylation levels
from three biological replicates as in (C). Total H3 or H4 was used for
normalization.
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Figure 20. H3 recognition by ZZ domain is required by full-length p300 to
acetylate H3K18 and H3K27 in cells.
(A) Western blot analysis of histone acetylation levels in whole cell extract of
293T cells transiently expressing full-length p300 or the ZZ mutants. (B)
Quantification of the indicated histone acetylation levels from three biological
replicates as in (A). Total H3 was used for normalization.
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3.5 Recognition of H3 by the ZZ domain is required for genome-wide p300
occupancy and p300-dependent deposition of H3K18ac and H3K27ac
To gain a deeper insight into the role of p300 ZZ domain in regulating
p300 occupancy and p300-dependent deposition of H3K18ac and H3K27ac
genome-wide, we performed ChIP-seq analysis in H1299 cells stably expressing
FLAG-p300BRPHZT or its counterpart harboring ZZ loss-of-function mutations,
N1671A or D1690A (Figure 21A-C). Western blotting analysis showed that the
WT and mutant FLAG-p300BRPHZT fragments are expressed at similar levels
(Figure 21B). We used the anti-Flag M2 antibody to ChIP for FLAG-p300BRPHZT
fragments and anti-H3K18ac and anti-H3K27ac antibodies to ChIP for respective
histone acetylation. The ChIPed DNA was sequenced using the Illumina Solexa
Hiseq 3000 at MD Anderson Cancer Center Science Park Next-Generation
Sequencing (NGS) Facility. We collaborated with Jiejun Shi from Dr. Wei Li’s lab
in Baylor College of Medicine (BCM) to analyze the ChIP-seq data. Our lab’s
previous data of anti-H3K4me1, anti-H3K27me3 and anti-H3K27ac ChIP-seq in
parental H1299 cells were also used in our analysis.
Anti-FLAG ChIP in the cells expressing WT FLAG-p300BRPHZT identified
679 p300BRPHZT binding sites. Compared with the previously published full-length
p300 binding sites (25, 167), p300BRPHZT binding sites are much broader and the
peaks are less sharp. To ensure to include the majority of p300BRPHZT binding
sites, we analyzed ChIP-seq signals spanning a ± 20 kb window centered on
binding peaks (Figure 21D). Based on pre-existing PTMs on H3K27 in H1299
cells, we divided the p300BRPHZT binding sites into two groups: H3K27 pre-
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acetylated regions (Group 1) and H3K27 pre-methylated regions (Group 2)
(Figure 21D). Group 1 sites are enriched with H3K27ac and H3K4me1, indicating
they are probably active enhancers and are likely targets of endogenous
p300/CBP. Because the peaks are already hyperacetylated, ectopic expression
of the p300BRPHZT fragment is not able to further increase acetylation levels at the
peaks. In contrast, a significant increase in H3K18ac and H3K27ac levels at the
hypoacetylated peak flanking regions was observed when ectopically expressing
WT p300BRPHZT (compared with the control cells expressing an empty vector)
(Figure 21D, Figure 22). Group 2 binding sites are preoccupied by H3K27me3
but not by H3K27ac or H3K18ac. This is not surprising as it has been shown
previously that p300/CBP also bind to a large number of poised regulatory
regions that are low in H3K27ac and high in H3K27me3 (167-169). Because
H3K27 at these regions is largely methylated across the entire +/- 20 kb windows
thus less accessible to p300 HAT, no significant increase in H3K18ac or
H3K27ac level was observed, despite the strong binding of p300BRPHZT in these
regions (Figure 21D).
In contrast to the WT p300BRPHZT protein, the two ZZ domain mutants,
N1671A and D1690A, were much less capable of gaining the chromatin binding
at both groups of sites, and consequently, the increase in H3K18ac and
H3K27ac occupancies at those sites was attenuated in the cells expressing
these mutants (Figure 21D, Figure 22).
We show in Figure 23 genome-browser views of four representative p300bound genes: NBPF1, NOTCH2NL, PDE4DIP and DMPK. While endogenous
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histone acetylation is strongly enriched at gene promoters, FLAG-p300BRPHZT
binds to much broader regions not only at promoters, but also in gene bodies and
intergenic regions. Binding of p300BRPHZT enhanced local histone acetylation
levels on both H3K18 and H3K27. However, loss-of-function mutations in ZZ
domain abolished p300BRPHZT bindings at those regions and consequently,
impaired acetylation on H3K18 and H3K27. These ChIP-seq results were
validated by ChIP-qPCR (Figure 24). Notably, the mutations of the ZZ domain
that abolish its H3-binding ability considerably decreased binding of p300BRPHZT
to individual genes (Figure 24A) and led to a notable reduction in the H3K18
(Figure 24B) and H3K27 (Figure 24C) acetylation levels on these genes. In
contrast, the H3K18 and H3K27 acetylation levels on ASCL1 and INSM1, the
negative control sites without p300BRPHZT binding, were not significantly changed
by ZZ mutations.
Similarly, the N1132A mutation that abrogates acetyllysine binding activity
of BRD resulted in a drastic decrease in p300BRPHZT occupancy and H3K18ac
and H3K27ac deposition at NBPF1, NOTCH2NL and DMPK target regions but
not the negative control regions (Figure 25). However, the p300BRPHZT occupancy
and H3K18ac and H3K27ac levels of PDE4DIP upstream regions were not
significantly affected by BRD mutation, indicating the chromatin association and
histone acetylation of p300BRPHZT are specifically dependent on ZZ-H3
recognition but not on BRD’s function at this site.
Together, these data suggest that both ZZ-H3 and BRD-acetyllysine
interactions are required for binding of p300 to chromatin and efficient histone
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H3K18/K27 acetylation in cells, corroborating the findings in salt fractionation
(Figure 14B), ChIP-WB (Figure 14C), in vitro HAT assay (Figure 17) and in vivo
histone acetylation analysis (Figures 19-20) described above.
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Figure 21. The ZZ domain is necessary to p300’s chromatin binding and
acetylation activity on H3K18 and H3K27 in cells.
(A) The workflow of samples preparation for ChIP-seq assay. (B) Western blot
analysis of the expression levels of wild type or mutated FLAG-p300BRPHZT level.
(C) Electrophoresis of sonicated DNAs for ChIP-seq. (D) Heatmap of normalized
H3K27ac (purple), H3K4me1 (green), H3K27me3 (scarlet), FLAG (brown) and
H3K18ac (blue) ChIP-seq signals centered on FLAG binding sites in a ±20kb
window in H1299 control cells and H1299 cells stably expressing wild type
FLAG-p300BRPHZT or the indicated ZZ mutants. The color keys represent signal
density.
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Figure 22. Box plots comparing FLAG, H3K18ac and H3K27ac occupancies
in different samples at FLAG-p300BRPHZT binding peaks.
All FLAG-p300BRPHZT peaks are divided into two groups as in Figure 21D. The
centerline of box represents the median and box limits indicate the 25th and
75th percentiles. Two-tailed paired Student’s t-test was used for statistical
analyses.
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Figure 23. Representative genome-browser views of ChIP-seq data.
Representative genome-browser views of the FLAG (brown), H3K18ac (blue)
and H3K27ac (purple) ChIP-seq signals on the indicated genes. The red lines
indicate the sites for ChIP-qPCR validation.
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Figure 24. ChIP-qPCR in H1299 cells stably expressing wild type FLAGp300BRPHZT or the ZZ mutants.
qPCR analysis of the FLAG-p300BRPHZT, H3K18ac and H3K27ac ChIP at target
loci (locations indicated by red line in Figure 23) and two negative control loci in
H1299 cells stably expressing wild type FLAG-p300BRPHZT or the ZZ mutants. IgG
or H3 ChIP was used for normalization.
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Figure 25. ChIP-qPCR in H1299 cells stably expressing wild type FLAGp300BRPHZT or the BRD mutant.
qPCR analysis of the FLAG-p300BRPHZT, H3K18ac and H3K27ac ChIP at target
loci and two negative control loci in H1299 cells stably expressing wild type
FLAG-p300BRPHZT or the N1132A mutant. IgG or H3 ChIP was used for
normalization.
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3.6 Conclusions
Our studies identify the ZZ domain of p300 as a reader specifically
recognizing the N-terminus of histone H3. This recognition is insensitive to
methylation or acetylation on H3 tail, a binding pattern distinct from all known H3
readers, suggesting the ZZ domain may constitute a novel group of histone
readers. Crystal structure of the ZZ-H3 complex reveals a negatively charged
cavity of ZZ that coordinates Ala1 and Arg2 of H3, suggesting a novel recognition
mode.
The H3-binding capability of ZZ and the acetyllysine binding ability of BRD
are both essential for chromatin association of p300 and acetylation of histones.
Specifically, the BRD-acetyllysine binding is necessary for p300 to catalyze
acetylation of virtually all lysine residues in H3 and H4, whereas the ZZ domain is
specifically required for p300 to acetylate primarily H3K27 and H3K18.
Collectively, the binding of p300 ZZ domain to H3 N-terminus provides a novel
intramolecular mechanism in regulating both chromatin recruitment and substrate
selectivity of p300.
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3.7 Discussion
Transcriptional coactivators p300 and CBP play critical roles in multiple
fundamental cellular processes such as cell proliferation, differentiation and
apoptosis. They contain multiple domains and most of these domains have been
well studied. However, the function of their ZZ domain is still elusive. In this
study, we discover that p300 ZZ domain is a reader for histone H3. It specifically
recognizes the first a few residues of H3 N-terminus, regardless of methylation or
acetylation status on H3. This unique feature distinguishes ZZ from all known
readers, as other readers are all sensitive to histone PTMs. The Kd value for the
p300 ZZ-H3 interaction is 8.8 μM (Figure 10B), which is in the range of binding
affinities exhibited by the majority of histone-binding modules (170-172),
corroborating the notion that the ZZ domain of p300 is a new member of
epigenetic readers that select for histone H3.
The ZZ domain of p300 possesses a novel structural mechanism for
histone H3 recognition. Importantly, key residues forming the negatively charged
binding site to contact with the Ala1 and Arg2 of H3, such as N1671, D1688 and
D1690, are highly conserved in multiple members of ZZ domain family (Figure
4B). It will be interesting to test whether other ZZ domains containing these
conserved residues also have H3-binding ability.
Although coactivator functions of p300/CBP are largely dependent on their
chromatin-binding capability (165, 173), the mechanism underlying p300/CBPchromatin association is not well studied. Transcription factors that bind specific
DNA sequences and other chromatin-binding factors can recruit p300/CBP to

89

chromatin through protein-protein interaction (46). Independent of the recruitment
by other proteins, p300 itself can directly bind to chromatin (165), which requires
the acetyllysine-binding ability of p300 BRD. We found that recognition of H3 by
p300 ZZ domain is also required for p300-chromatin association, which provides
another mechanism for recruiting p300 to chromatin. By ChIP and salt
fractionation assays, we revealed the importance of ZZ and BRD for p300’s
binding to chromatin, as deletion or loss-of-function mutations of either domain
dramatically reduced p300-chromatin association globally and at specific target
regions (Figures 13, 14, 24 and 25). Furthermore, simultaneous mutations of
both domains further reduced chromatin binding compared with single domain
deficiencies, indicating that ZZ and BRD may collaborate in promoting p300’s
chromatin recruitment. Interestingly, double mutations did not completely abolish
p300’s chromatin binding (Figures 13 and 14), suggesting that mechanisms other
than ZZ and BRD may exist. For instance, the TAZ2 domain can recruit p300 to
chromatin through interacting with transcription factors (46).
Genome-wide analysis of p300BRPHZT occupancy by ChIP-seq analysis
identified 679 peaks, which are much fewer than that of full-length p300 (25,
167). This is likely because the p300BRPHZT fragment lacks a number of proteininteracting domains in the full-length protein that also contribute to p300chromatin binding. Nevertheless, the p300BRPHZT binding sites can be classified
into two groups based on the pre-existing modifications on H3K27: H3K27 preacetylated regions (Group 1) and H3K27 pre-methylated regions (Group 2)
(Figure 21D). Group 1 sites are likely active enhancers containing high level of
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H3K4me1 and H3K27ac while Group 2 binding sites are probably silenced or
poised enhancers. Both BRD and ZZ domains are required for p300 binding at
both groups of sites, however, certain level of specificity still remains. For
example, the p300BRPHZT occupies the PDE4DIP upstream region; mutations of
the ZZ mutation, but not BRD, affect the binding. As H4 acetylation levels may be
low in this region, it is likely that the ZZ-H3 interaction plays a dominant role in
p300 chromatin binding.
Most known histone readers recognize specific histone modifications, thus
promoting recruitment of the protein or protein complex to specific chromatin loci.
However, the ZZ-H3 binding is independent of any H3 modifications, suggesting
that ZZ domain alone is not be able to recruit p300 to specific chromatin regions.
So, what is the significance of the “non-specific” ZZ-H3 interaction in p300’s
chromatin recruitment? Inspired by the ideas of Manning et al. (165), we
proposed the following model (Figure 26). Prior to p300 being recruited to
specific target regions by interacting with transcription factors, the recognition of
H3 by ZZ domain may account for the initial step of p300 to associate with
chromatin (Figure 26A). This close chromatin proximity would allow DNA-bound
transcription factors to quickly find p300 and then to recruit it to specific target
regions (Figure 26B). Alternatively, after p300 is recruited to specific regions by
transcription factors, the ZZ-H3 binding stabilizes p300’s association with
chromatin to ensure transcription is successfully activated (Figure 26C). More
biochemical and cell-based experiments need to be done to test this model.
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Both p300 and CBP are promiscuous acetyltransferases with hundreds of
substrates, including multiple sites of all core histones (19). However, depletion
of both p300 and CBP specifically reduces global levels of H3K18ac and
H3K27ac in mammalian cells (12, 13). The reason why acetylation on H3K18
and H3K27 is dominantly dependent on p300/CBP is currently unknown. We
show that the ability of p300 to acetylate primarily H3K18 and H3K27 largely
relies on the binding of the ZZ domain to the N-terminus of H3. A model of the
p300HAT+ZZ-H3 complex (generated by Yi Zhang from Kutateladze lab) using the
simulated annealing method and the crystal structures of p300BRPH and p300 ZZH3 reveals a ~38 Å distance between the H3A1-binding site of ZZ and the
catalytic site in the HAT domain (Figure 27). This distance is too long for Lys4 or
Lys9 of H3 to occupy the active site of the HAT domain and thus be acetylated in
cis when the N-terminus of H3 is locked through the interaction with ZZ.
However, the distal lysine residues (K18 and K27) in the H3 tail can reach the
active site. Furthermore, the substrate-binding groove of the HAT domain is
highly negatively charged and would favor the binding of positively-charged H3
tail. Our in vitro and in vivo data and the structure model collectively suggest that
binding of p300 ZZ domain to the N-terminus of H3 provides selectivity of the
adjacent HAT domain toward the distal lysine sites in H3, such as H3K18 and
H3K27.
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Figure 26. The proposed functions of ZZ domain-mediated p300 chromatin
recruitment.
(A) Before p300 is recruited to specific target regions by transcription factors, the
recognition of H3 by ZZ domain may represent the initial step to associate p300
with chromatin. (B) This association would then allow DNA-bound transcription
factors to recruit p300 from chromatin, rather than from solution, to specific target
regions more efficiently. (C) After p300 is recruited to specific regions by
transcription factors, its interaction with chromatin is stabilized by the ZZ-H3
binding to ensure transcription is successfully activated.
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Figure 27. The structural basis of ZZ-mediated HAT specificity toward the
distal lysine sites in H3.
A model of the p300HAT+ZZ region in complex with H31-31 peptide generated by Yi
Zhang from Kutateladze lab. Electrostatic surface potential of p300 HAT is
colored blue (positive charge) and red (negative charge) with the histone H3
peptide shown in green. The side chains of H3K4, K9, K18 and K27 are colored
yellow.
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Chapter 4. p300 Is Required for Maintenance of SCLC Cell Growth

4.1 Depletion of p300 impedes SCLC cell proliferation
Cancer cells are highly dependent on dysregulated transcriptional
programs gained during tumorigenesis to maintain their continued growth, a
phenomenon called “transcriptional addiction” (174). As transcriptional
coactivators, p300/CBP have been extensively studied in many types of cancers,
however, their roles in SCLC are elusive. High p300/CBP expression was
reported to be associated with poor overall survival for resected SCLC patients
(111). In SCLC, disease maintenance is addicted to overexpression of
oncogenes such as MYC, MYCL, MYCN, NFIB and SOX2, which is driven by
super-enhancers containing extraordinarily high level of H3K27 acetylation (153).
Considering p300 and CBP are the dominant HATs catalyzing H3K27
acetylation, they likely play important roles in maintaining active super-enhancers
in SCLC. Based on these known facts, we hypothesized that p300/CBP are
required for SCLC disease maintenance by activating oncogenes.
First, we examined the expression levels of p300/CBP in a number of
mouse and human SCLC cells. SCLC cells isolated from primary tumors of
genetically engineered mouse models (GEMM) constitute a good model because
of their simple genetic background. Kp1 and Kp3 are two primary SCLC tumor
cell lines isolated from the GEMM with conditional Trp53 Rb1 double knockout in
lung (175); Kp12 and 259-2 cells are isolated from conditional Trp53 Rb1 p130
triple knockout GEMM that have accelerated SCLC tumorigenesis compared with
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Trp53 Rb1 double knockout GEMM (176) (Figure 28A). ID43 cells are lung
epithelial neuroendocrine cells isolated from conditional Trp53 Rb1 p130 triple
knockout GEMM before they become malignant (preSC), thus serving as a nontumorigenic control for SCLC cells (177) (Figure 28A). By analyzing the whole
cell lysate of these cells, we found that most GEMM SCLC cells have higher
p300 levels than the ID43 preSC cells (Figure 28B). The expression levels of
CBP are also slightly higher in the GEMM SCLC cells. However, despite of the
increased p300/CBP levels, we did not observe a dramatic elevation of global
H3K27ac level in GEMM SCLC cells compared with ID43 cell (Figure 28B).
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Figure 28. p300 is overexpressed in murine SCLC cell lines.
(A) The sources of GEMM SCLC cell lines. (B) Western blot analysis of p300,
CBP and H3K27ac levels in the indicated SCLC cell lines.
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To determine the role of p300/CBP in maintenance of SCLC cell growth,
we depleted Ep300 or Crebbp gene using a lentiviral CRISPR-Cas9 system. Two
distinct gRNAs targeting the 5’ end of the CDS were used for each gene and
non-targeting (NT) gRNA served as control. Western blotting confirmed that each
target gene was successfully depleted at protein level in all cell lines without
significantly affecting the level of its close paralog (Figure 29A). Proliferation
assays showed that p300-depleted Kp1, Kp3, Kp12 and 259-2 cells grow much
more slowly than their NT control cells (Fig 29B). Compared to p300 depletion,
CBP depletion had little (Kp1 and 259-2) or no (Kp3 and Kp12) proliferation
defect (Fig 29B). Together, these results demonstrate that p300, but not CBP, is
essential to murine SCLC cell proliferation.
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Figure 29. The depletion of p300 impedes murine SCLC cells proliferation.
(A) Western blot analysis of p300 and CBP levels in the control and p300/CBPdepleted murine SCLC cells. (B) The proliferation of control and p300/CBPdepleted murine SCLC cells.

99

Compared with GEMM SCLC cells, human SCLC cells are much more
heterogeneous both genetically and epigenetically. For example, they have
distinct mutation status of CREBBP/EP300 genes, amplification of different MYC
family genes, and various expression levels of neuroendocrine transcription
factors. To study the role of CBP/p300 in human SCLC cells with different
backgrounds, we chose SCLC cells with (1) WT CBP and WT p300 (H69, H82
and H2171); (2) WT p300 and mutated CBP (H1048 and H209); and (3) WT CBP
and mutated p300 (H524 and H1836). The detailed mutation information of those
cells is listed in Table 5. Immortalized human bronchial epithelial cell (HBEC)
was used as a non-cancer control. Western blot analysis showed that all SCLC
cell lines except H1836 have much higher levels of p300 than HBEC and all cell
lines except H209 have greatly increased CBP level compared with HBEC cells
(Figure 30). Loss of CBP in H209 cell is due to translocation and loss-ofheterozygosity (LOH) (90, 158). It is interesting that cell lines carrying mutated
p300 (H524) or CBP (H1048) still had higher levels of p300 and CBP,
respectively, than control cells. There are two possibilities: (1) the mutations are
heterozygous and the remaining WT allele is still functional; or (2) the mutations
do not completely abolish the proteins’ functions. For example, the CBP
mutation, S1680del, in H1048 cells is not located within any known domain
(Table 5), therefore its functional consequence is hard to predict. In H524 cells,
although the mutation in the HAT domain abrogates the HAT activity (95), the
mutant p300 may still interacts with other proteins to help to assemble an
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activating complex. Nevertheless, our results suggest that p300 and CBP are
overexpressed in human SCLC cells regardless of their genetic mutation status.
We next examined global H3K18ac and H3K27ac levels in these cells
(Figure 30). Although the levels of H3K27ac in SCLC cells are not significantly
higher than the non-tumorigenic HBEC cells, H3K18ac levels are much higher in
the SCLC cells compared with HBEC. The global H3K18ac and H3K27ac levels
correlate with the total levels of p300 and CBP proteins in most human SCLC
cells except for the H69 cells.

Cell line
HBEC
A549
H1299
H1048
H1836
H209
H2171
H524
H69
H82
ID43
Kp1
Kp3

Cell type
Human control cell
Human NSCLC
Human NSCLC
Human SCLC
Human SCLC
Human SCLC
Human SCLC
Human SCLC
Human SCLC
Human SCLC
Mouse pre-SCLC
Mouse SCLC
Mouse SCLC

EP300 status
WT
WT
WT
WT
p.S1396P
WT
WT
p.F1090L, Y1503S
WT
WT
WT
WT
WT

CREBBP status
WT
WT
WT
p.S1680del
WT
Homozygous Deletions
WT
WT
WT
WT
WT
WT
WT

Kp3+GFP+Luc

Mouse SCLC

WT

WT

Kp12
259-2

Mouse SCLC
Mouse SCLC

WT
WT

WT
WT

Table 5. The mutation status of EP300 and CREBBP genes in lung cancer
cell lines used in this study.
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Figure 30. p300 and CBP are overexpressed in human SCLC cell lines.
Western blot analysis of p300, CBP, H3K18ac and H3K27ac levels in the
indicated SCLC cell lines.
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Human SCLC cells can be classified by the expression levels of NE
lineage transcription factors, ASCL1 or NEUROD1. ASCL1-high (cells expressing
high level of ASCL1 but low level of NEUROD1) and NEUROD1-high (cells
expressing high level of NEUROD1 but low level of ASCL1) are two dominant
groups (178) that have different epigenetic landscapes (179). To examine the
role of p300/CBP in both groups of human SCLC cells, we depleted
CREBBP/EP300 in both ASCL1-high (H69 cells) and NEUROD1-high (H82 cells)
cells and determined cell proliferation. Two distinct gRNAs targeting the 5’ end of
the CDS were used for each gene and non-targeting (NT) gRNA served as
control. Western blotting confirmed that each target gene was successfully
depleted at protein level in both cell lines without significantly affecting the level
of its close paralog (Figure 31A). Depleting p300 or CBP did not significantly
affect the global H3K27ac level in these two cell lines (Figure 31A), suggesting
the potential redundancy between p300 and CBP in maintaining the global
H3K27ac level.
Proliferation assays showed that p300 depletion led to a severe
proliferation defect in both H69 and H82 cells, whereas CBP depletion only
slightly impeded cell proliferation (Figure 31B), suggesting that p300, but not
CBP, is crucial to human SCLC cell proliferation. Those results are in agreement
with our observations in murine SCLC cells.
NSCLC is another subtype of lung cancer accounting for ~85% of lung
cancer cases. To examine whether p300 and CBP are required by NSCLC, we
depleted EP300 or CREBBP gene in two representative NSCLC cell lines, A549

103

and H1299, and HBEC cell, and measured cell proliferation. Surprisingly, cell
proliferation was not affected by p300 or CBP depletion in these cell lines (Figure
32), indicating that the dependency on p300 is specific to SCLC but not to
NSCLC or normal lung cells.
In summary, we found that p300 is overexpressed in both murine and
human SCLC cells. It is required for the maintenance of cell growth in both
murine and human SCLC cells. Although CBP is also overexpressed in human
SCLC, but in most SCLC cells, CBP is not absolutely required for cell growth
maintenance.
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Figure 31. The depletion of p300 impedes human SCLC cells proliferation.
(A) Western blot analysis of p300 and CBP levels in the control and p300/CBPdepleted human SCLC cells. (B) The proliferation of control and p300/CBPdepleted H69 and H82 cells.
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Figure 32. The depletion of p300 does not affect the proliferation of human
NSCLC cells and normal lung epithelial cell.
(A) The proliferation of control and p300/CBP-depleted H1299 and A549 cells.
(B) The proliferation of control and p300/CBP-depleted HBEC cells.
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4.2 Depletion of p300 attenuates oncogene activation in SCLC cells
CBP/p300 are critical transcriptional coactivators that control the
expression of key cancer-related genes, especially those associated with superenhancers (103). To determine the functional differences between p300 and CBP
in SCLC cell proliferation, we assessed the expression of a few key oncogenes in
p300 or CBP depleted cells. We chose to study the expression changes of MYC
family genes because: (1) MYC family genes are known to play critical roles in
the tumorigenesis/maintenance of both murine (177, 180) and human (151, 156)
SCLCs; (2) MYC family genes are associated with super-enhancers in human
SCLCs and are thus likely direct targets of p300/CBP (153). MYC family genes
include 3 members: MYC, MYCL1 and MYCN. A large number of human SCLCs
have the amplification of one MYC family gene. For example, H69 cell is MYCNamplified whereas H82 has MYC amplification. The amplified MYC member
usually has much higher expression level than the other 2 members and
becomes the dominant one in that cell (156, 181). We performed RT-qPCR
assays to compare the expression levels of MYC, MYCL and MYCN in these two
cell lines (Figure 33A). Consistent with the amplification status, MYC levels in
H82 are ~1,000-fold higher than that in H69 while its MYCN level was ~1,000fold lower than that of H69. We also observed that H82 has higher MYCL1
expression level than H69. It is possible that among the MYC family members,
MYCN or MYC plays the most dominant oncogenic role in H69 or H82,
respectively.
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Interestingly, in H69, depletion of p300 or CBP reduced the expression of
MYCN and MYC but not MYCL1. The decrease in MYCN level was much more
significant in p300-depleted cells than in CBP-depleted cells (Figure 33B). The
decreased expression of MYCN was also observed in p300- or CBP-depleted
H82 cells. But the reduction of MYC level was only found in p300-depleted H82
cells but not in CBP-depleted ones (Figure 33B). These results suggest that
expression of the dominant MYC family member shows more dependency on
p300 than CBP in both cell lines. This may partially explain why p300 depletion
caused much more severe proliferation defect than CBP depletion (Figure 31B).
According to the work of Drs. Kwok-kin Wong and Richard Young (153),
MYCN is driven by super-enhancers in H69 but not in H82 while MYC is driven
by super-enhancers in H82 but not in H69 (Figure 34A), which is consistent with
their relative expression levels (Figure 33A) and amplification status in these 2
cell lines. Considering p300 is one of the main acetyltransferases of H3K18ac
and H3K27ac, we proposed that p300 is required for the acetylation of H3K18
and H3K27 at super-enhancers associated with the dominant MYC family gene
in SCLC cell. We chose two regions of the published MYC super-enhancer in
H82 cell as examples and performed H3K18ac and H3K27ac ChIP-qPCR in
p300-depleted and NT control H82 cells. Significant decrease of H3K27ac level
at both regions was observed in p300-depleted cells (Figure 34B). The depletion
of p300 also led to a severe drop of H3K18ac level at SE1 region. The decrease
of both histone markers at MYC super-enhancers resulted from p300 depletion is
consistent with the reduced MYC expression. Taken together, we found p300 is
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required for sustaining the histone acetylation and expression of superenhancers-associated oncogenes in SCLC cells.
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Figure 33. Expression activation of the dominant MYC family gene is
dependent on p300.
(A) RT-qPCR analysis of 3 MYC family genes in H69 and H82 cells. (B) RTqPCR analysis of 3 MYC family genes in control and p300/CBP-depleted H69
and H82 cells.
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Figure 34. Histone acetylation at MYC super-enhancer regions requires
p300.
(A) The genome-browser views of H3K27ac at MYC and MYCN super-enhancer
regions. The raw data tracks are from Gene Expression Omnibus with the
accession number GSE62614 (153). The red lines indicate the sites for ChIPqPCR in (B). SE: super-enhancer. (B) qPCR analysis of the H3K27ac level at two
MYC super-enhancer regions.
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4.3 Conclusions
In this study, we show that p300 and CBP are overexpressed in both
murine and human SCLC cells. Depletion of p300, but not CBP, impedes SCLC
cell proliferation. Both p300 and CBP are required for sustaining the expression
of oncogenes, for example, the MYC family genes, in SCLC cells. However, the
expression of the dominant MYC family gene that is associated with superenhancers shows more dependency on p300 than CBP. Consistently, p300, but
not CBP, is essential for maintenance of SCLC cell growth.
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4.4 Discussion
SCLC is the most aggressive subtype of lung cancer with an unmet need
for effective treatment (182). The molecular basis of this disease is poorly
understood. Here we found that p300 is required for the proliferation of both
murine and human SCLC cells. The proliferation defect caused by p300
depletion was observed in all SCLC cell lines tested. However, more cell lines
need to be tested before we can conclude that p300 dependency is a ubiquitous
mechanism in SCLC, a highly heterogeneous disease. It will also be important to
test in the future whether p300 depletion also attenuates SCLC tumor growth in a
xenograft or allograft model. Importantly, p300 depletion does not dramatically
affect the proliferation of NSCLC cells or normal lung epithelial cell, implying that
inhibiting p300 may be a potential SCLC treatment method with low toxicity to
normal lung cell.
Despite of the high sequence similarity between p300 and CBP, CBP is
not required for cell proliferation in the SCLC cell lines tested. Because of the
relatively high mutation rate (13~15%) of CREBBP/EP300 in SCLC (95, 136), it
has been previously predicted that both CREBBP and EP300 are tumor
suppressor genes (183). Most CREBBP alterations are nonsense mutations,
deletions, frameshifts and translocations (Figure 5B), which are likely loss-offunction. Consistent with the mutation status of CREBBP, the laboratory of Dr.
David MacPherson recently reported that lung neuroendocrine-specific triple
knockout of Trp53, Rb1 and Crebbp in mice accelerates SCLC tumorigenesis
compared with Trp53 Rb1 double knockout mice, indicating Crebbp is a tumor
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suppressor gene in murine SCLC (184). However, this paper did not mention the
role of p300 in SCLC. In fact, the mutation pattern of EP300 in SCLC is distinct
from that of CREBBP. The majority of EP300 alterations are missense mutations
with unknown consequences, though only a few of mutations within p300 HAT
domain have been confirmed to reduce HAT activity (95). Therefore, the mutation
status of EP300 in SCLC does not conflict with our results that p300 is required
in maintaining the continuous growth of SCLC cells.
An explanation for the functional differences between p300 and CBP in
SCLC may be that they target different genes (185). In H69 and H82 cells,
activation of the dominant MYC family gene that is associated with superenhancers relies more on p300 than on CBP, which may reflect the differences in
their target genes. Unfortunately, we only have a small amount of preliminary
data on how p300 and CBP regulate oncogenes in SCLC cells. RNA-seq and
H3K27ac ChIP-seq analysis using control cell, p300- or CBP-depleted cells will
provide more comprehensive information to help us understand the molecular
basis of the p300-dependency in SCLC cell proliferation in the future.
Overall, although still preliminary, our data start to shed light on the critical
functions of p300 in SCLC. Future studies will bring further insights into the
molecular mechanisms of SCLC maintenance and evaluate p300 inhibition as a
new therapeutic strategy for SCLC patients.
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Chapter 5. Future Directions

5.1 Determining the physiological importance of p300 ZZ domain
p300 is a key transcription coactivator important to both development and
diseases. Our findings that the ZZ domain is required for both chromatin binding
and histone acetylation, the basic molecular functions of p300, suggesting that
the ZZ domain is likely critical for p300 to exert its functions in both physiological
and pathological settings. It is particularly interesting to me to determine the
functional importance of the ZZ domain in human cancers.
Although there is no cancer-related mutation hotspot in p300 ZZ domain
reported in TCGA, we did find dozens of genetic mutations occurring in the ZZ
domain coding regions, albeit with low frequency, from cBioPortal
(https://www.cbioportal.org) (119, 120) and Catalogue of Somatic Mutations in
Cancer (COSMIC, https://cancer.sanger.ac.uk/cosmic) (186). All up-to-date
mutations located in p300 ZZ domain are listed in Table 6 and Figure 35A. The
effect of those mutations on p300 ZZ’s function is currently unknown.
In our preliminary studies, we expressed and purified recombinant ZZ
domain mutants mimicking a few TCGA mutations, including R1680C/H, W1681*
and D1688H (Figure 35B) and tested their histone-binding activity. Histone
peptide pull-down assays showed that the H3-binding activity is reduced in
R1680C and W1681A and abolished in the D1688K mutant (Figure 35C). These
preliminary data suggest that cancer-related mutations can abrogate the function
of ZZ, implying the histone-binding activity of p300 ZZ domain is indeed
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important to tumorigenesis. In the future, it will be interesting to study the function
of p300 ZZ domain in tumorigenesis using a proper cancer model. For instance,
the colon cancer mutation of ZZ domain, R1680C, can be introduced into
endogenous EP300 gene by CRISPR/Cas9-mediated DNA cutting followed by
homology-directed repair using single-stranded oligodeoxynucleotides in colon
epithelial cells. Single clones containing a R1680C point mutation will be selected
and examined for their cell growth and survival in culture. We’ll also establish
xenograft models using those cells for measuring tumor growth in vivo.
Mechanistically, the epigenome and transcriptome of parental and ZZ-mutated
cells will be assessed by p300 and histone ChIP-seq and RNA-seq, respectively.
The ZZ domain is required for p300-dependent H3K18 and H3K27
acetylation and the BRD is required for the acetylation of all lysine residues on
H3 and H4 by p300. Importantly, these two domains seem to cooperate in
regulating the HAT activity of p300. The inhibitors of p300 BRD showed good
anti-cancer effect in hematopoietic malignancies (43, 118). In the future, we also
plan to determine whether ZZ mutations can sensitize cells to those BRD
inhibitor, which will be beneficial to the development of targeted therapies.
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Sample ID
MFE296 cell line
ATLL_A-01
ATL014
TCGA-BG-A0MG-01
OSCC-GB_01670111
ESCC_E11
MBC_71
Pat_59_B
TCGA-DM-A1D0-01
TCGA-F5-6813-01
PLK106Ca
TCGA-ZR-A9CJ-01
PD8141a
ATL359
coadread_dfci_2016_2768
T2768
Pat_24_Pre
PAJMVC
ID32
SW948 cell line
MTS-T0713
TCGA-P3-A5Q5-01
TCGA-GR-A4D6-01
HCT-116 cell line
P-0003104-T01-IM5
P-0010591-T01-IM5

Cancer Study
CCLE (Novartis/Broad 2012)
Lymphoma/leukemia (COSMIC)
Lymphoma/leukemia (COSMIC)
Uterine (TCGA)
Oral (COSMIC)
Esophagus (COSMIC)
MBL (Sickkids 2016)
Melanoma (COSMIC)
Colon (TCGA)
Colon (TCGA)
Colon (COSMIC)
Esophagus (TCGA)
AML (COSMIC)
Lymphoma/leukemia (COSMIC)
Colorectal (DFCI 2016)
Colon (COSMIC)
Melanoma (Broad 2012)
Kidney (COSMIC)
AML (COSMIC)
CCLE (Novartis/Broad 2012)
Breast (METABRIC)
Head & neck (TCGA)
DLBC (TCGA)
NCI-60
MSK-IMPACT
MSK-IMPACT

Gene
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300
EP300

AA change
R1665H
T1669I
T1669I
E1672*
E1672*
C1673Y
E1678Q
T1679I
R1680H
R1680H
R1680C
R1680C
W1681*
C1683Y
V1685I
V1685I
C1686Y
C1686*
C1686fs
X1687_splice
D1688H
D1688H
T1694A
N1700fs
H1703Y
E1706*

Table 6. Mutations in p300 ZZ domain occurring in cancers.
Data are collected from cBioPortal (www.cbioportal.org) (119, 120) and COSMIC
(https://cancer.sanger.ac.uk/cosmic) (186). The diagram view of these listed
mutations is in Figure 35A.
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Type
Missense
Missense
Missense
Nonsense
Nonsense
Missense
Missense
Missense
Missense
Missense
Missense
Missense
Nonsense
Missense
Missense
Missense
Missense
Nonsense
FS del
Splice
Missense
Missense
Missense
FS del
Missense
Nonsense

Figure 35. Mutations of p300 ZZ domain occurring in cancers.
(A) The diagram view of all the mutations of p300 ZZ domain occurring in
cancers (also listed in Table 6). Diagram is generated using the online tool
ProteinPaint (https://pecan.stjude.cloud/proteinpaint) (187). (B) Examples of
p300 ZZ domain mutations that occur in cancers. (C) Peptide pull-down assays
using wild type and mutated p300 ZZ domain.
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5.2 Determining the role of p300 in SCLC maintenance
Our preliminary data has shown that p300 is necessary to SCLC cell
proliferation in cell culture. This is an interesting observation, however, much
more need to be done to reveal the role of p300 in SCLC maintenance. It would
be of great interest to determine in the future whether p300 depletion impedes
SCLC tumor growth in xenograft or allograft models. We can perform RNA-seq
and ChIP-seq to further examine the transcriptomic and epigenomic changes
resulted from p300, CBP, or double depletions. It is anticipated that depletion of
p300, CBP or both will lead to a drastic decrease in the expression of oncogenes
associated with super-enhancers in SCLC tumors.
Interestingly, a recent report shows that SCLC cells are not sensitive to A485, a potent small molecule inhibitor targeting p300/CBP HAT domain (15),
indicating that the function of p300 in SCLC cell proliferation may not require the
HAT activity. Indeed, p300 is essential for the assembly of a transcription
activation complex using protein-interaction domains, which may contribute to
disease maintenance independent of its HAT activity. This makes it urgent to
identify the protein domains or minimal regions of p300 that are critical for its
biological functions in SCLC. To identify such essential domains, we will perform
a CRISPR/Cas9-based dropout screening in SCLC cells using a tilling gRNA
library targeting the EP300 gene exons encoding the full-length p300 protein.
The gRNAs targeting critical domains or regions are expected to have
significantly lower enrichment. After the critical domains/regions are identified,
rescue assays will be performed using constructs containing the deletion of each
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critical domain or region in p300-depleted SCLC cells. If specific inhibitors for the
critical domains are available, we will also test whether SCLC cells are sensitive
to those compounds.
Collectively, these studies will depict a detailed picture of the molecular
mechanisms of p300 and extend our understanding of critical roles of p300 in
important biological processes. Furthermore, elucidating the role of p300 in
SCLC will help to bring insights into the molecular basis of SCLC maintenance
and may provide p300 as a new therapeutic target for treatment of SCLC.

120

Chapter 6. References

1.

Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner. 1994. E1Aassociated p300 and CREB-associated CBP belong to a conserved family
of coactivators. Cell 77: 799-800.

2.

Vo, N., and R. H. Goodman. 2001. CREB-binding protein and p300 in
transcriptional regulation. The Journal of biological chemistry 276: 1350513508.

3.

Yee, S. P., and P. E. Branton. 1985. Detection of cellular proteins
associated with human adenovirus type 5 early region 1A polypeptides.
Virology 147: 142-153.

4.

Whyte, P., N. M. Williamson, and E. Harlow. 1989. Cellular targets for
transformation by the adenovirus E1A proteins. Cell 56: 67-75.

5.

Stein, R. W., M. Corrigan, P. Yaciuk, J. Whelan, and E. Moran. 1990.
Analysis of E1A-mediated growth regulation functions: binding of the 300kilodalton cellular product correlates with E1A enhancer repression
function and DNA synthesis-inducing activity. Journal of virology 64: 44214427.

6.

Eckner, R., M. E. Ewen, D. Newsome, M. Gerdes, J. A. DeCaprio, J. B.
Lawrence, and D. M. Livingston. 1994. Molecular cloning and functional
analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals
a protein with properties of a transcriptional adaptor. Genes &
development 8: 869-884.

121

7.

Chrivia, J. C., R. P. Kwok, N. Lamb, M. Hagiwara, M. R. Montminy, and R.
H. Goodman. 1993. Phosphorylated CREB binds specifically to the
nuclear protein CBP. Nature 365: 855-859.

8.

Ogryzko, V. V., R. L. Schiltz, V. Russanova, B. H. Howard, and Y.
Nakatani. 1996. The transcriptional coactivators p300 and CBP are
histone acetyltransferases. Cell 87: 953-959.

9.

Bannister, A. J., and T. Kouzarides. 1996. The CBP co-activator is a
histone acetyltransferase. Nature 384: 641-643.

10.

Farria, A., W. Li, and S. Y. Dent. 2015. KATs in cancer: functions and
therapies. Oncogene 34: 4901-4913.

11.

Schiltz, R. L., C. A. Mizzen, A. Vassilev, R. G. Cook, C. D. Allis, and Y.
Nakatani. 1999. Overlapping but distinct patterns of histone acetylation by
the human coactivators p300 and PCAF within nucleosomal substrates.
The Journal of biological chemistry 274: 1189-1192.

12.

Jin, Q., L. R. Yu, L. Wang, Z. Zhang, L. H. Kasper, J. E. Lee, C. Wang, P.
K. Brindle, S. Y. Dent, and K. Ge. 2011. Distinct roles of GCN5/PCAFmediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear
receptor transactivation. The EMBO journal 30: 249-262.

13.

Horwitz, G. A., K. Zhang, M. A. McBrian, M. Grunstein, S. K. Kurdistani,
and A. J. Berk. 2008. Adenovirus small e1a alters global patterns of
histone modification. Science 321: 1084-1085.

14.

Weinert, B. T., T. Narita, S. Satpathy, B. Srinivasan, B. K. Hansen, C.
Scholz, W. B. Hamilton, B. E. Zucconi, W. W. Wang, W. R. Liu, J. M.

122

Brickman, E. A. Kesicki, A. Lai, K. D. Bromberg, P. A. Cole, and C.
Choudhary. 2018. Time-Resolved Analysis Reveals Rapid Dynamics and
Broad Scope of the CBP/p300 Acetylome. Cell 174: 231-244 e212.
15.

Lasko, L. M., C. G. Jakob, R. P. Edalji, W. Qiu, D. Montgomery, E. L.
Digiammarino, T. M. Hansen, R. M. Risi, R. Frey, V. Manaves, B. Shaw,
M. Algire, P. Hessler, L. T. Lam, T. Uziel, E. Faivre, D. Ferguson, F. G.
Buchanan, R. L. Martin, M. Torrent, G. G. Chiang, K. Karukurichi, J. W.
Langston, B. T. Weinert, C. Choudhary, P. de Vries, J. H. Van Drie, D.
McElligott, E. Kesicki, R. Marmorstein, C. Sun, P. A. Cole, S. H.
Rosenberg, M. R. Michaelides, A. Lai, and K. D. Bromberg. 2017.
Discovery of a selective catalytic p300/CBP inhibitor that targets lineagespecific tumours. Nature 550: 128-132.

16.

Das, C., M. S. Lucia, K. C. Hansen, and J. K. Tyler. 2009. CBP/p300mediated acetylation of histone H3 on lysine 56. Nature 459: 113-117.

17.

Vempati, R. K., R. S. Jayani, D. Notani, A. Sengupta, S. Galande, and D.
Haldar. 2010. p300-mediated acetylation of histone H3 lysine 56 functions
in DNA damage response in mammals. The Journal of biological
chemistry 285: 28553-28564.

18.

Chen, C. C., J. J. Carson, J. Feser, B. Tamburini, S. Zabaronick, J. Linger,
and J. K. Tyler. 2008. Acetylated lysine 56 on histone H3 drives chromatin
assembly after repair and signals for the completion of repair. Cell 134:
231-243.

123

19.

Dancy, B. M., and P. A. Cole. 2015. Protein lysine acetylation by
p300/CBP. Chemical reviews 115: 2419-2452.

20.

Chan, H. M., and N. B. La Thangue. 2001. p300/CBP proteins: HATs for
transcriptional bridges and scaffolds. Journal of cell science 114: 23632373.

21.

Kalkhoven, E. 2004. CBP and p300: HATs for different occasions.
Biochemical pharmacology 68: 1145-1155.

22.

Chen, J., and Q. Li. 2011. Life and death of transcriptional co-activator
p300. Epigenetics : official journal of the DNA Methylation Society 6: 957961.

23.

Wang, Z., C. Zang, K. Cui, D. E. Schones, A. Barski, W. Peng, and K.
Zhao. 2009. Genome-wide mapping of HATs and HDACs reveals distinct
functions in active and inactive genes. Cell 138: 1019-1031.

24.

Heintzman, N. D., R. K. Stuart, G. Hon, Y. Fu, C. W. Ching, R. D.
Hawkins, L. O. Barrera, S. Van Calcar, C. Qu, K. A. Ching, W. Wang, Z.
Weng, R. D. Green, G. E. Crawford, and B. Ren. 2007. Distinct and
predictive chromatin signatures of transcriptional promoters and
enhancers in the human genome. Nature genetics 39: 311-318.

25.

Visel, A., M. J. Blow, Z. Li, T. Zhang, J. A. Akiyama, A. Holt, I. PlajzerFrick, M. Shoukry, C. Wright, F. Chen, V. Afzal, B. Ren, E. M. Rubin, and
L. A. Pennacchio. 2009. ChIP-seq accurately predicts tissue-specific
activity of enhancers. Nature 457: 854-858.

124

26.

Park, S., R. L. Stanfield, M. A. Martinez-Yamout, H. J. Dyson, I. A. Wilson,
and P. E. Wright. 2017. Role of the CBP catalytic core in intramolecular
SUMOylation and control of histone H3 acetylation. Proceedings of the
National Academy of Sciences of the United States of America 114:
E5335-E5342.

27.

Delvecchio, M., J. Gaucher, C. Aguilar-Gurrieri, E. Ortega, and D. Panne.
2013. Structure of the p300 catalytic core and implications for chromatin
targeting and HAT regulation. Nature structural & molecular biology 20:
1040-1046.

28.

Thompson, P. R., D. Wang, L. Wang, M. Fulco, N. Pediconi, D. Zhang, W.
An, Q. Ge, R. G. Roeder, J. Wong, M. Levrero, V. Sartorelli, R. J. Cotter,
and P. A. Cole. 2004. Regulation of the p300 HAT domain via a novel
activation loop. Nature structural & molecular biology 11: 308-315.

29.

Karanam, B., L. Jiang, L. Wang, N. L. Kelleher, and P. A. Cole. 2006.
Kinetic and mass spectrometric analysis of p300 histone acetyltransferase
domain autoacetylation. The Journal of biological chemistry 281: 4029240301.

30.

Ortega, E., S. Rengachari, Z. Ibrahim, N. Hoghoughi, J. Gaucher, A. S.
Holehouse, S. Khochbin, and D. Panne. 2018. Transcription factor
dimerization activates the p300 acetyltransferase. Nature.

31.

Liu, X., L. Wang, K. Zhao, P. R. Thompson, Y. Hwang, R. Marmorstein,
and P. A. Cole. 2008. The structural basis of protein acetylation by the
p300/CBP transcriptional coactivator. Nature 451: 846-850.

125

32.

Black, J. C., J. E. Choi, S. R. Lombardo, and M. Carey. 2006. A
mechanism for coordinating chromatin modification and preinitiation
complex assembly. Molecular cell 23: 809-818.

33.

Rack, J. G., T. Lutter, G. E. Kjaereng Bjerga, C. Guder, C. Ehrhardt, S.
Varv, M. Ziegler, and R. Aasland. 2014. The PHD finger of p300
influences its ability to acetylate histone and non-histone targets. Journal
of molecular biology 426: 3960-3972.

34.

Shi, X., T. Hong, K. L. Walter, M. Ewalt, E. Michishita, T. Hung, D. Carney,
P. Pena, F. Lan, M. R. Kaadige, N. Lacoste, C. Cayrou, F. Davrazou, A.
Saha, B. R. Cairns, D. E. Ayer, T. G. Kutateladze, Y. Shi, J. Cote, K. F.
Chua, and O. Gozani. 2006. ING2 PHD domain links histone H3 lysine 4
methylation to active gene repression. Nature 442: 96-99.

35.

Sanchez, R., and M. M. Zhou. 2011. The PHD finger: a versatile
epigenome reader. Trends in biochemical sciences 36: 364-372.

36.

Park, S., M. A. Martinez-Yamout, H. J. Dyson, and P. E. Wright. 2013. The
CH2 domain of CBP/p300 is a novel zinc finger. FEBS letters 587: 25062511.

37.

Hammitzsch, A., C. Tallant, O. Fedorov, A. O'Mahony, P. E. Brennan, D.
A. Hay, F. O. Martinez, M. H. Al-Mossawi, J. de Wit, M. Vecellio, C. Wells,
P. Wordsworth, S. Muller, S. Knapp, and P. Bowness. 2015. CBP30, a
selective CBP/p300 bromodomain inhibitor, suppresses human Th17
responses. Proceedings of the National Academy of Sciences of the
United States of America 112: 10768-10773.

126

38.

Ghosh, S., A. Taylor, M. Chin, H. R. Huang, A. R. Conery, J. A. Mertz, A.
Salmeron, P. J. Dakle, D. Mele, A. Cote, H. Jayaram, J. W. Setser, F. Poy,
G. Hatzivassiliou, D. DeAlmeida-Nagata, P. Sandy, C. Hatton, F. A.
Romero, E. Chiang, T. Reimer, T. Crawford, E. Pardo, V. G. Watson, V.
Tsui, A. G. Cochran, L. Zawadzke, J. C. Harmange, J. E. Audia, B. M.
Bryant, R. T. Cummings, S. R. Magnuson, J. L. Grogan, S. F. Bellon, B. K.
Albrecht, R. J. Sims, 3rd, and J. M. Lora. 2016. Regulatory T Cell
Modulation by CBP/EP300 Bromodomain Inhibition. The Journal of
biological chemistry 291: 13014-13027.

39.

Nguyen, U. T., L. Bittova, M. M. Muller, B. Fierz, Y. David, B. HouckLoomis, V. Feng, G. P. Dann, and T. W. Muir. 2014. Accelerated
chromatin biochemistry using DNA-barcoded nucleosome libraries. Nature
methods 11: 834-840.

40.

Kraus, W. L., E. T. Manning, and J. T. Kadonaga. 1999. Biochemical
analysis of distinct activation functions in p300 that enhance transcription
initiation with chromatin templates. Molecular and cellular biology 19:
8123-8135.

41.

Tang, Z., W. Y. Chen, M. Shimada, U. T. Nguyen, J. Kim, X. J. Sun, T.
Sengoku, R. K. McGinty, J. P. Fernandez, T. W. Muir, and R. G. Roeder.
2013. SET1 and p300 act synergistically, through coupled histone
modifications, in transcriptional activation by p53. Cell 154: 297-310.

42.

Fonte, C., J. Grenier, A. Trousson, A. Chauchereau, O. Lahuna, E. E.
Baulieu, M. Schumacher, and C. Massaad. 2005. Involvement of {beta}-

127

catenin and unusual behavior of CBP and p300 in glucocorticosteroid
signaling in Schwann cells. Proceedings of the National Academy of
Sciences of the United States of America 102: 14260-14265.
43.

Conery, A. R., R. C. Centore, A. Neiss, P. J. Keller, S. Joshi, K. L.
Spillane, P. Sandy, C. Hatton, E. Pardo, L. Zawadzke, A. Bommi-Reddy,
K. E. Gascoigne, B. M. Bryant, J. A. Mertz, and R. J. Sims. 2016.
Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as
a therapeutic strategy to target the IRF4 network in multiple myeloma.
eLife 5.

44.

Chakravarti, D., V. J. LaMorte, M. C. Nelson, T. Nakajima, I. G. Schulman,
H. Juguilon, M. Montminy, and R. M. Evans. 1996. Role of CBP/P300 in
nuclear receptor signalling. Nature 383: 99-103.

45.

Goodman, R. H., and S. Smolik. 2000. CBP/p300 in cell growth,
transformation, and development. Genes & development 14: 1553-1577.

46.

Wang, F., C. B. Marshall, and M. Ikura. 2013. Transcriptional/epigenetic
regulator CBP/p300 in tumorigenesis: structural and functional versatility
in target recognition. Cellular and molecular life sciences : CMLS 70:
3989-4008.

47.

Mayr, B., and M. Montminy. 2001. Transcriptional regulation by the
phosphorylation-dependent factor CREB. Nature reviews. Molecular cell
biology 2: 599-609.

48.

Kwok, R. P., J. R. Lundblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger,
R. G. Brennan, S. G. Roberts, M. R. Green, and R. H. Goodman. 1994.

128

Nuclear protein CBP is a coactivator for the transcription factor CREB.
Nature 370: 223-226.
49.

Radhakrishnan, I., G. C. Perez-Alvarado, D. Parker, H. J. Dyson, M. R.
Montminy, and P. E. Wright. 1997. Solution structure of the KIX domain of
CBP bound to the transactivation domain of CREB: a model for
activator:coactivator interactions. Cell 91: 741-752.

50.

Berk, A. J. 2005. Recent lessons in gene expression, cell cycle control,
and cell biology from adenovirus. Oncogene 24: 7673-7685.

51.

Hamamori, Y., V. Sartorelli, V. Ogryzko, P. L. Puri, H. Y. Wu, J. Y. Wang,
Y. Nakatani, and L. Kedes. 1999. Regulation of histone acetyltransferases
p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein
E1A. Cell 96: 405-413.

52.

Chakravarti, D., V. Ogryzko, H. Y. Kao, A. Nash, H. Chen, Y. Nakatani,
and R. M. Evans. 1999. A viral mechanism for inhibition of p300 and
PCAF acetyltransferase activity. Cell 96: 393-403.

53.

Perissi, V., J. S. Dasen, R. Kurokawa, Z. Wang, E. Korzus, D. W. Rose, C.
K. Glass, and M. G. Rosenfeld. 1999. Factor-specific modulation of
CREB-binding protein acetyltransferase activity. Proceedings of the
National Academy of Sciences of the United States of America 96: 36523657.

54.

Madison, D. L., P. Yaciuk, R. P. Kwok, and J. R. Lundblad. 2002.
Acetylation of the adenovirus-transforming protein E1A determines

129

nuclear localization by disrupting association with importin-alpha. The
Journal of biological chemistry 277: 38755-38763.
55.

Saint Just Ribeiro, M., M. L. Hansson, and A. E. Wallberg. 2007. A proline
repeat domain in the Notch co-activator MAML1 is important for the p300mediated acetylation of MAML1. The Biochemical journal 404: 289-298.

56.

Hansson, M. L., A. E. Popko-Scibor, M. Saint Just Ribeiro, B. M. Dancy,
M. J. Lindberg, P. A. Cole, and A. E. Wallberg. 2009. The transcriptional
coactivator MAML1 regulates p300 autoacetylation and HAT activity.
Nucleic acids research 37: 2996-3006.

57.

Fryer, C. J., E. Lamar, I. Turbachova, C. Kintner, and K. A. Jones. 2002.
Mastermind mediates chromatin-specific transcription and turnover of the
Notch enhancer complex. Genes & development 16: 1397-1411.

58.

Bose, D. A., G. Donahue, D. Reinberg, R. Shiekhattar, R. Bonasio, and S.
L. Berger. 2017. RNA Binding to CBP Stimulates Histone Acetylation and
Transcription. Cell 168: 135-149 e122.

59.

Kim, T. K., M. Hemberg, J. M. Gray, A. M. Costa, D. M. Bear, J. Wu, D. A.
Harmin, M. Laptewicz, K. Barbara-Haley, S. Kuersten, E. MarkenscoffPapadimitriou, D. Kuhl, H. Bito, P. F. Worley, G. Kreiman, and M. E.
Greenberg. 2010. Widespread transcription at neuronal activity-regulated
enhancers. Nature 465: 182-187.

60.

Huang, W. C., and C. C. Chen. 2005. Akt phosphorylation of p300 at Ser1834 is essential for its histone acetyltransferase and transcriptional
activity. Molecular and cellular biology 25: 6592-6602.

130

61.

Chen, Y. J., Y. N. Wang, and W. C. Chang. 2007. ERK2-mediated Cterminal serine phosphorylation of p300 is vital to the regulation of
epidermal growth factor-induced keratin 16 gene expression. The Journal
of biological chemistry 282: 27215-27228.

62.

Wan, W., Z. You, Y. Xu, L. Zhou, Z. Guan, C. Peng, C. C. L. Wong, H. Su,
T. Zhou, H. Xia, and W. Liu. 2017. mTORC1 Phosphorylates
Acetyltransferase p300 to Regulate Autophagy and Lipogenesis.
Molecular cell 68: 323-335 e326.

63.

Yuan, L. W., J. W. Soh, and I. B. Weinstein. 2002. Inhibition of histone
acetyltransferase function of p300 by PKCdelta. Biochimica et biophysica
acta 1592: 205-211.

64.

Jang, E. R., J. D. Choi, G. Jeong, and J. S. Lee. 2010. Phosphorylation of
p300 by ATM controls the stability of NBS1. Biochemical and biophysical
research communications 397: 637-643.

65.

Wang, Q. E., C. Han, R. Zhao, G. Wani, Q. Zhu, L. Gong, A. Battu, I.
Racoma, N. Sharma, and A. A. Wani. 2013. p38 MAPK- and Akt-mediated
p300 phosphorylation regulates its degradation to facilitate nucleotide
excision repair. Nucleic acids research 41: 1722-1733.

66.

Lee, Y. H., S. A. Coonrod, W. L. Kraus, M. A. Jelinek, and M. R. Stallcup.
2005. Regulation of coactivator complex assembly and function by protein
arginine methylation and demethylimination. Proceedings of the National
Academy of Sciences of the United States of America 102: 3611-3616.

131

67.

Xu, W., H. Chen, K. Du, H. Asahara, M. Tini, B. M. Emerson, M.
Montminy, and R. M. Evans. 2001. A transcriptional switch mediated by
cofactor methylation. Science 294: 2507-2511.

68.

Chevillard-Briet, M., D. Trouche, and L. Vandel. 2002. Control of CBP coactivating activity by arginine methylation. The EMBO journal 21: 54575466.

69.

Ceschin, D. G., M. Walia, S. S. Wenk, C. Duboe, C. Gaudon, Y. Xiao, L.
Fauquier, M. Sankar, L. Vandel, and H. Gronemeyer. 2011. Methylation
specifies distinct estrogen-induced binding site repertoires of CBP to
chromatin. Genes & development 25: 1132-1146.

70.

Girdwood, D., D. Bumpass, O. A. Vaughan, A. Thain, L. A. Anderson, A.
W. Snowden, E. Garcia-Wilson, N. D. Perkins, and R. T. Hay. 2003. P300
transcriptional repression is mediated by SUMO modification. Molecular
cell 11: 1043-1054.

71.

Kuo, H. Y., C. C. Chang, J. C. Jeng, H. M. Hu, D. Y. Lin, G. G. Maul, R. P.
Kwok, and H. M. Shih. 2005. SUMO modification negatively modulates the
transcriptional activity of CREB-binding protein via the recruitment of
Daxx. Proceedings of the National Academy of Sciences of the United
States of America 102: 16973-16978.

72.

Tanaka, Y., I. Naruse, T. Hongo, M. Xu, T. Nakahata, T. Maekawa, and S.
Ishii. 2000. Extensive brain hemorrhage and embryonic lethality in a
mouse null mutant of CREB-binding protein. Mech Dev 95: 133-145.

132

73.

Yao, T. P., S. P. Oh, M. Fuchs, N. D. Zhou, L. E. Ch'ng, D. Newsome, R.
T. Bronson, E. Li, D. M. Livingston, and R. Eckner. 1998. Gene dosagedependent embryonic development and proliferation defects in mice
lacking the transcriptional integrator p300. Cell 93: 361-372.

74.

Oike, Y., N. Takakura, A. Hata, T. Kaname, M. Akizuki, Y. Yamaguchi, H.
Yasue, K. Araki, K. Yamamura, and T. Suda. 1999. Mice homozygous for
a truncated form of CREB-binding protein exhibit defects in hematopoiesis
and vasculo-angiogenesis. Blood 93: 2771-2779.

75.

Kung, A. L., V. I. Rebel, R. T. Bronson, L. E. Ch'ng, C. A. Sieff, D. M.
Livingston, and T. P. Yao. 2000. Gene dose-dependent control of
hematopoiesis and hematologic tumor suppression by CBP. Genes &
development 14: 272-277.

76.

Tanaka, Y., I. Naruse, T. Maekawa, H. Masuya, T. Shiroishi, and S. Ishii.
1997. Abnormal skeletal patterning in embryos lacking a single Cbp allele:
a partial similarity with Rubinstein-Taybi syndrome. Proceedings of the
National Academy of Sciences of the United States of America 94: 1021510220.

77.

Petrij, F., R. H. Giles, H. G. Dauwerse, J. J. Saris, R. C. Hennekam, M.
Masuno, N. Tommerup, G. J. van Ommen, R. H. Goodman, D. J. Peters,
and et al. 1995. Rubinstein-Taybi syndrome caused by mutations in the
transcriptional co-activator CBP. Nature 376: 348-351.

78.

Solomon, B. D., D. L. Bodian, A. Khromykh, G. G. Mora, B. C. Lanpher, R.
K. Iyer, R. Baveja, J. G. Vockley, and J. E. Niederhuber. 2015. Expanding

133

the phenotypic spectrum in EP300-related Rubinstein-Taybi syndrome.
American journal of medical genetics. Part A 167: 1111-1116.
79.

Rubinstein, J. H., and H. Taybi. 1963. Broad thumbs and toes and facial
abnormalities. A possible mental retardation syndrome. Am J Dis Child
105: 588-608.

80.

Oike, Y., A. Hata, T. Mamiya, T. Kaname, Y. Noda, M. Suzuki, H. Yasue,
T. Nabeshima, K. Araki, and K. Yamamura. 1999. Truncated CBP protein
leads to classical Rubinstein-Taybi syndrome phenotypes in mice:
implications for a dominant-negative mechanism. Human molecular
genetics 8: 387-396.

81.

Kasper, L. H., F. Boussouar, P. A. Ney, C. W. Jackson, J. Rehg, J. M. van
Deursen, and P. K. Brindle. 2002. A transcription-factor-binding surface of
coactivator p300 is required for haematopoiesis. Nature 419: 738-743.

82.

Rebel, V. I., A. L. Kung, E. A. Tanner, H. Yang, R. T. Bronson, and D. M.
Livingston. 2002. Distinct roles for CREB-binding protein and p300 in
hematopoietic stem cell self-renewal. Proceedings of the National
Academy of Sciences of the United States of America 99: 14789-14794.

83.

Korzus, E., M. G. Rosenfeld, and M. Mayford. 2004. CBP histone
acetyltransferase activity is a critical component of memory consolidation.
Neuron 42: 961-972.

84.

Alarcon, J. M., G. Malleret, K. Touzani, S. Vronskaya, S. Ishii, E. R.
Kandel, and A. Barco. 2004. Chromatin acetylation, memory, and LTP are

134

impaired in CBP+/- mice: a model for the cognitive deficit in RubinsteinTaybi syndrome and its amelioration. Neuron 42: 947-959.
85.

Barrett, R. M., M. Malvaez, E. Kramar, D. P. Matheos, A. Arrizon, S. M.
Cabrera, G. Lynch, R. W. Greene, and M. A. Wood. 2011. Hippocampal
focal knockout of CBP affects specific histone modifications, long-term
potentiation, and long-term memory. Neuropsychopharmacology : official
publication of the American College of Neuropsychopharmacology 36:
1545-1556.

86.

Korzus, E. 2017. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Advances in experimental medicine and biology 978: 39-62.

87.

Martincorena, I., and P. J. Campbell. 2015. Somatic mutation in cancer
and normal cells. Science 349: 1483-1489.

88.

Gayther, S. A., S. J. Batley, L. Linger, A. Bannister, K. Thorpe, S. F. Chin,
Y. Daigo, P. Russell, A. Wilson, H. M. Sowter, J. D. Delhanty, B. A.
Ponder, T. Kouzarides, and C. Caldas. 2000. Mutations truncating the
EP300 acetylase in human cancers. Nature genetics 24: 300-303.

89.

Bryan, E. J., V. J. Jokubaitis, N. L. Chamberlain, S. W. Baxter, E. Dawson,
D. Y. Choong, and I. G. Campbell. 2002. Mutation analysis of EP300 in
colon, breast and ovarian carcinomas. International journal of cancer.
Journal international du cancer 102: 137-141.

90.

Kishimoto, M., T. Kohno, K. Okudela, A. Otsuka, H. Sasaki, C. Tanabe, T.
Sakiyama, C. Hirama, I. Kitabayashi, J. D. Minna, S. Takenoshita, and J.
Yokota. 2005. Mutations and deletions of the CBP gene in human lung

135

cancer. Clinical cancer research : an official journal of the American
Association for Cancer Research 11: 512-519.
91.

Li, Y. Y., G. J. Hanna, A. C. Laga, R. I. Haddad, J. H. Lorch, and P. S.
Hammerman. 2015. Genomic analysis of metastatic cutaneous squamous
cell carcinoma. Clinical cancer research : an official journal of the
American Association for Cancer Research 21: 1447-1456.

92.

Pasqualucci, L., D. Dominguez-Sola, A. Chiarenza, G. Fabbri, A. Grunn,
V. Trifonov, L. H. Kasper, S. Lerach, H. Tang, J. Ma, D. Rossi, A.
Chadburn, V. V. Murty, C. G. Mullighan, G. Gaidano, R. Rabadan, P. K.
Brindle, and R. Dalla-Favera. 2011. Inactivating mutations of
acetyltransferase genes in B-cell lymphoma. Nature 471: 189-195.

93.

Morin, R. D., M. Mendez-Lago, A. J. Mungall, R. Goya, K. L. Mungall, R.
D. Corbett, N. A. Johnson, T. M. Severson, R. Chiu, M. Field, S. Jackman,
M. Krzywinski, D. W. Scott, D. L. Trinh, J. Tamura-Wells, S. Li, M. R.
Firme, S. Rogic, M. Griffith, S. Chan, O. Yakovenko, I. M. Meyer, E. Y.
Zhao, D. Smailus, M. Moksa, S. Chittaranjan, L. Rimsza, A. BrooksWilson, J. J. Spinelli, S. Ben-Neriah, B. Meissner, B. Woolcock, M. Boyle,
H. McDonald, A. Tam, Y. Zhao, A. Delaney, T. Zeng, K. Tse, Y.
Butterfield, I. Birol, R. Holt, J. Schein, D. E. Horsman, R. Moore, S. J.
Jones, J. M. Connors, M. Hirst, R. D. Gascoyne, and M. A. Marra. 2011.
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.
Nature 476: 298-303.

136

94.

Haery, L., J. G. Lugo-Pico, R. A. Henry, A. J. Andrews, and T. D. Gilmore.
2014. Histone acetyltransferase-deficient p300 mutants in diffuse large B
cell lymphoma have altered transcriptional regulatory activities and are
required for optimal cell growth. Molecular cancer 13: 29.

95.

Peifer, M., L. Fernandez-Cuesta, M. L. Sos, J. George, D. Seidel, L. H.
Kasper, D. Plenker, F. Leenders, R. Sun, T. Zander, R. Menon, M. Koker,
I. Dahmen, C. Muller, V. Di Cerbo, H. U. Schildhaus, J. Altmuller, I.
Baessmann, C. Becker, B. de Wilde, J. Vandesompele, D. Bohm, S.
Ansen, F. Gabler, I. Wilkening, S. Heynck, J. M. Heuckmann, X. Lu, S. L.
Carter, K. Cibulskis, S. Banerji, G. Getz, K. S. Park, D. Rauh, C. Grutter,
M. Fischer, L. Pasqualucci, G. Wright, Z. Wainer, P. Russell, I. Petersen,
Y. Chen, E. Stoelben, C. Ludwig, P. Schnabel, H. Hoffmann, T. Muley, M.
Brockmann, W. Engel-Riedel, L. A. Muscarella, V. M. Fazio, H. Groen, W.
Timens, H. Sietsma, E. Thunnissen, E. Smit, D. A. Heideman, P. J.
Snijders, F. Cappuzzo, C. Ligorio, S. Damiani, J. Field, S. Solberg, O. T.
Brustugun, M. Lund-Iversen, J. Sanger, J. H. Clement, A. Soltermann, H.
Moch, W. Weder, B. Solomon, J. C. Soria, P. Validire, B. Besse, E.
Brambilla, C. Brambilla, S. Lantuejoul, P. Lorimier, P. M. Schneider, M.
Hallek, W. Pao, M. Meyerson, J. Sage, J. Shendure, R. Schneider, R.
Buttner, J. Wolf, P. Nurnberg, S. Perner, L. C. Heukamp, P. K. Brindle, S.
Haas, and R. K. Thomas. 2012. Integrative genome analyses identify key
somatic driver mutations of small-cell lung cancer. Nature genetics 44:
1104-1110.

137

96.

Sobulo, O. M., J. Borrow, R. Tomek, S. Reshmi, A. Harden, B.
Schlegelberger, D. Housman, N. A. Doggett, J. D. Rowley, and N. J.
ZeleznikLe. 1997. MLL is fused to CBP, a histone acetyltransferase, in
therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3).
Proceedings of the National Academy of Sciences of the United States of
America 94: 8732-8737.

97.

Rowley, J. D., S. Reshmi, O. Sobulo, T. Musvee, J. Anastasi, S.
Raimondi, N. R. Schneider, J. C. Barredo, E. S. Cantu, B. Schlegelberger,
F. Behm, N. A. Doggett, J. Borrow, and N. ZeleznikLe. 1997. All patients
with the T(11;16)(q23;p13.3) that involves MLL and CBP have treatmentrelated hematologic disorders. Blood 90: 535-541.

98.

Ida, K., I. Kitabayashi, T. Taki, M. Taniwaki, K. Noro, M. Yamamoto, M.
Ohki, and Y. Hayashi. 1997. Adenoviral E1A-associated protein p300 is
involved in acute myeloid leukemia with t(11;22)(q23;q13). Blood 90:
4699-4704.

99.

Giles, R. H., J. G. Dauwerse, C. Higgins, F. Petrij, J. W. Wessels, G. C.
Beverstock, H. Dohner, M. Jotterand-Bellomo, J. H. F. Falkenburg, R. M.
Slater, G. J. B. van Ommen, A. Hagemeijer, B. A. van der Reijden, and M.
H. Breuning. 1997. Detection of CBP rearrangements in acute
myelogenous leukemia with t(8;16). Leukemia 11: 2087-2096.

100.

Kitabayashi, I., Y. Aikawa, A. Yokoyama, F. Hosoda, M. Nagai, N. Kakazu,
T. Abe, and M. Ohki. 2001. Fusion of MOZ and p300 histone

138

acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13)
chromosome translocation. Leukemia 15: 89-94.
101.

Ionov, Y., S. Matsui, and J. K. Cowell. 2004. A role for p300/CREB binding
protein genes in promoting cancer progression in colon cancer cell lines
with microsatellite instability. Proceedings of the National Academy of
Sciences of the United States of America 101: 1273-1278.

102.

Iyer, N. G., S. F. Chin, H. Ozdag, Y. Daigo, D. E. Hu, M. Cariati, K.
Brindle, S. Aparicio, and C. Caldas. 2004. p300 regulates p53-dependent
apoptosis after DNA damage in colorectal cancer cells by modulation of
PUMA/p21 levels. Proceedings of the National Academy of Sciences of
the United States of America 101: 7386-7391.

103.

Jiang, Y., A. Ortega-Molina, H. Geng, H. Y. Ying, K. Hatzi, S. Parsa, D.
McNally, L. Wang, A. S. Doane, X. Agirre, M. Teater, C. Meydan, Z. Li, D.
Poloway, S. Wang, D. Ennishi, D. W. Scott, K. R. Stengel, J. E. Kranz, E.
Holson, S. Sharma, J. W. Young, C. S. Chu, R. G. Roeder, R.
Shaknovich, S. W. Hiebert, R. D. Gascoyne, W. Tam, O. Elemento, H. G.
Wendel, and A. M. Melnick. 2017. CREBBP Inactivation Promotes the
Development of HDAC3-Dependent Lymphomas. Cancer discovery 7: 3853.

104.

Zhang, J., S. Vlasevska, V. A. Wells, S. Nataraj, A. B. Holmes, R. Duval,
S. N. Meyer, T. Mo, K. Basso, P. K. Brindle, S. Hussein, R. Dalla-Favera,
and L. Pasqualucci. 2017. The CREBBP Acetyltransferase Is a

139

Haploinsufficient Tumor Suppressor in B-cell Lymphoma. Cancer
discovery.
105.

Horton, S. J., G. Giotopoulos, H. Yun, S. Vohra, O. Sheppard, R.
Bashford-Rogers, M. Rashid, A. Clipson, W. I. Chan, D. Sasca, L.
Yiangou, H. Osaki, F. Basheer, P. Gallipoli, N. Burrows, A. Erdem, A.
Sybirna, S. Foerster, W. Zhao, T. Sustic, A. Petrunkina Harrison, E.
Laurenti, J. Okosun, D. Hodson, P. Wright, K. G. Smith, P. Maxwell, J.
Fitzgibbon, M. Q. Du, D. J. Adams, and B. J. P. Huntly. 2017. Early loss of
Crebbp confers malignant stem cell properties on lymphoid progenitors.
Nature cell biology 19: 1093-1104.

106.

Garcia-Ramirez, I., S. Tadros, I. Gonzalez-Herrero, A. Martin-Lorenzo, G.
Rodriguez-Hernandez, D. Moore, L. Ruiz-Roca, O. Blanco, D. AlonsoLopez, J. L. Rivas, K. Hartert, R. Duval, D. Klinkebiel, M. Bast, J. Vose, M.
Lunning, K. Fu, T. Greiner, F. Rodrigues-Lima, R. Jimenez, F. J. G.
Criado, M. B. G. Cenador, P. Brindle, C. Vicente-Duenas, A. Alizadeh, I.
Sanchez-Garcia, and M. R. Green. 2017. Crebbp loss cooperates with
Bcl2 overexpression to promote lymphoma in mice. Blood 129: 26452656.

107.

Okosun, J., C. Bodor, J. Wang, S. Araf, C. Y. Yang, C. Pan, S. Boller, D.
Cittaro, M. Bozek, S. Iqbal, J. Matthews, D. Wrench, J. Marzec, K.
Tawana, N. Popov, C. O'Riain, D. O'Shea, E. Carlotti, A. Davies, C. H.
Lawrie, A. Matolcsy, M. Calaminici, A. Norton, R. J. Byers, C. Mein, E.
Stupka, T. A. Lister, G. Lenz, S. Montoto, J. G. Gribben, Y. Fan, R.

140

Grosschedl, C. Chelala, and J. Fitzgibbon. 2014. Integrated genomic
analysis identifies recurrent mutations and evolution patterns driving the
initiation and progression of follicular lymphoma. Nature genetics 46: 176181.
108.

Debes, J. D., T. J. Sebo, C. M. Lohse, L. M. Murphy, D. A. Haugen, and
D. J. Tindall. 2003. p300 in prostate cancer proliferation and progression.
Cancer research 63: 7638-7640.

109.

Yokomizo, C., K. Yamaguchi, Y. Itoh, T. Nishimura, A. Umemura, M.
Minami, K. Yasui, H. Mitsuyoshi, H. Fujii, N. Tochiki, T. Nakajima, T.
Okanoue, and T. Yoshikawa. 2011. High expression of p300 in HCC
predicts shortened overall survival in association with enhanced epithelial
mesenchymal transition of HCC cells. Cancer Lett 310: 140-147.

110.

Hou, X., Y. Li, R. Z. Luo, J. H. Fu, J. H. He, L. J. Zhang, and H. X. Yang.
2012. High expression of the transcriptional co-activator p300 predicts
poor survival in resectable non-small cell lung cancers. European journal
of surgical oncology : the journal of the European Society of Surgical
Oncology and the British Association of Surgical Oncology 38: 523-530.

111.

Gao, Y., J. Geng, X. Hong, J. Qi, Y. Teng, Y. Yang, D. Qu, and G. Chen.
2014. Expression of p300 and CBP is associated with poor prognosis in
small cell lung cancer. International journal of clinical and experimental
pathology 7: 760-767.

112.

Zhong, J., L. Ding, L. R. Bohrer, Y. Pan, P. Liu, J. Zhang, T. J. Sebo, R. J.
Karnes, D. J. Tindall, J. van Deursen, and H. Huang. 2014. p300

141

acetyltransferase regulates androgen receptor degradation and PTENdeficient prostate tumorigenesis. Cancer research 74: 1870-1880.
113.

Ianculescu, I., D. Y. Wu, K. D. Siegmund, and M. R. Stallcup. 2012.
Selective roles for cAMP response element-binding protein binding protein
and p300 protein as coregulators for androgen-regulated gene expression
in advanced prostate cancer cells. The Journal of biological chemistry
287: 4000-4013.

114.

Lee, J. H., B. Yang, A. J. Lindahl, N. Damaschke, M. D. Boersma, W.
Huang, E. Corey, D. F. Jarrard, and J. M. Denu. 2017. Identifying
Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate
Cancer Development. ACS chemical biology 12: 2804-2814.

115.

Giotopoulos, G., W. I. Chan, S. J. Horton, D. Ruau, P. Gallipoli, A. Fowler,
C. Crawley, E. Papaemmanuil, P. J. Campbell, B. Gottgens, J. M. Van
Deursen, P. A. Cole, and B. J. Huntly. 2016. The epigenetic regulators
CBP and p300 facilitate leukemogenesis and represent therapeutic targets
in acute myeloid leukemia. Oncogene 35: 279-289.

116.

Pattabiraman, D. R., J. Sun, D. H. Dowhan, S. Ishii, and T. J. Gonda.
2009. Mutations in multiple domains of c-Myb disrupt interaction with
CBP/p300 and abrogate myeloid transforming ability. Mol Cancer Res 7:
1477-1486.

117.

Pattabiraman, D. R., C. McGirr, K. Shakhbazov, V. Barbier, K. Krishnan,
P. Mukhopadhyay, P. Hawthorne, A. Trezise, J. Ding, S. M. Grimmond, P.
Papathanasiou, W. S. Alexander, A. C. Perkins, J. P. Levesque, I. G.

142

Winkler, and T. J. Gonda. 2014. Interaction of c-Myb with p300 is required
for the induction of acute myeloid leukemia (AML) by human AML
oncogenes. Blood 123: 2682-2690.
118.

Picaud, S., O. Fedorov, A. Thanasopoulou, K. Leonards, K. Jones, J.
Meier, H. Olzscha, O. Monteiro, S. Martin, M. Philpott, A. Tumber, P.
Filippakopoulos, C. Yapp, C. Wells, K. H. Che, A. Bannister, S. Robson,
U. Kumar, N. Parr, K. Lee, D. Lugo, P. Jeffrey, S. Taylor, M. L. Vecellio, C.
Bountra, P. E. Brennan, A. O'Mahony, S. Velichko, S. Muller, D. Hay, D. L.
Daniels, M. Urh, N. B. La Thangue, T. Kouzarides, R. Prinjha, J.
Schwaller, and S. Knapp. 2015. Generation of a Selective Small Molecule
Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy. Cancer
research 75: 5106-5119.

119.

Cerami, E., J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy,
A. Jacobsen, C. J. Byrne, M. L. Heuer, E. Larsson, Y. Antipin, B. Reva, A.
P. Goldberg, C. Sander, and N. Schultz. 2012. The cBio cancer genomics
portal: an open platform for exploring multidimensional cancer genomics
data. Cancer discovery 2: 401-404.

120.

Gao, J., B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer,
Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, and N.
Schultz. 2013. Integrative analysis of complex cancer genomics and
clinical profiles using the cBioPortal. Sci Signal 6: pl1.

121.

Legge, G. B., M. A. Martinez-Yamout, D. M. Hambly, T. Trinh, B. M. Lee,
H. J. Dyson, and P. E. Wright. 2004. ZZ domain of CBP: an unusual zinc

143

finger fold in a protein interaction module. Journal of molecular biology
343: 1081-1093.
122.

Ponting, C. P., D. J. Blake, K. E. Davies, J. Kendrick-Jones, and S. J.
Winder. 1996. ZZ and TAZ: new putative zinc fingers in dystrophin and
other proteins. Trends in biochemical sciences 21: 11-13.

123.

Barresi, R., and K. P. Campbell. 2006. Dystroglycan: from biosynthesis to
pathogenesis of human disease. Journal of cell science 119: 199-207.

124.

Ishikawa-Sakurai, M., M. Yoshida, M. Imamura, K. E. Davies, and E.
Ozawa. 2004. ZZ domain is essentially required for the physiological
binding of dystrophin and utrophin to beta-dystroglycan. Human molecular
genetics 13: 693-702.

125.

Sanz, L., M. T. Diaz-Meco, H. Nakano, and J. Moscat. 2000. The atypical
PKC-interacting protein p62 channels NF-kappaB activation by the IL-1TRAF6 pathway. The EMBO journal 19: 1576-1586.

126.

Danielsen, J. R., L. K. Povlsen, B. H. Villumsen, W. Streicher, J. Nilsson,
M. Wikstrom, S. Bekker-Jensen, and N. Mailand. 2012. DNA damageinducible SUMOylation of HERC2 promotes RNF8 binding via a novel
SUMO-binding Zinc finger. J Cell Biol 197: 179-187.

127.

Diehl, C., M. Akke, S. Bekker-Jensen, N. Mailand, W. Streicher, and M.
Wikstrom. 2016. Structural analysis of a complex between small ubiquitinlike modifier 1 (SUMO1) and the ZZ domain of CREB-binding Protein
(CBP/p300) reveals a new interaction surface on SUMO. The Journal of
biological chemistry.

144

128.

Semenova, E. A., R. Nagel, and A. Berns. 2015. Origins, genetic
landscape, and emerging therapies of small cell lung cancer. Genes &
development 29: 1447-1462.

129.

Kato, Y., T. B. Ferguson, D. E. Bennett, and T. H. Burford. 1969. Oat cell
carcinoma of the lung. A review of 138 cases. Cancer 23: 517-524.

130.

Sutherland, K. D., N. Proost, I. Brouns, D. Adriaensen, J. Y. Song, and A.
Berns. 2011. Cell of origin of small cell lung cancer: inactivation of Trp53
and Rb1 in distinct cell types of adult mouse lung. Cancer cell 19: 754764.

131.

Park, K. S., M. C. Liang, D. M. Raiser, R. Zamponi, R. R. Roach, S. J.
Curtis, Z. Walton, B. E. Schaffer, C. M. Roake, A. F. Zmoos, C. Kriegel, K.
K. Wong, J. Sage, and C. F. Kim. 2011. Characterization of the cell of
origin for small cell lung cancer. Cell cycle 10: 2806-2815.

132.

Micke, P., A. Faldum, T. Metz, K. M. Beeh, F. Bittinger, J. G. Hengstler,
and R. Buhl. 2002. Staging small cell lung cancer: Veterans Administration
Lung Study Group versus International Association for the Study of Lung
Cancer--what limits limited disease? Lung Cancer 37: 271-276.

133.

Kalemkerian, G. P., W. Akerley, P. Bogner, H. Borghaei, L. Q. Chow, R. J.
Downey, L. Gandhi, A. K. Ganti, R. Govindan, J. C. Grecula, J. Hayman,
R. S. Heist, L. Horn, T. Jahan, M. Koczywas, B. W. Loo, Jr., R. E. Merritt,
C. A. Moran, H. B. Niell, J. O'Malley, J. D. Patel, N. Ready, C. M. Rudin,
C. C. Williams, Jr., K. Gregory, M. Hughes, and N. National

145

Comprehensive Cancer. 2013. Small cell lung cancer. Journal of the
National Comprehensive Cancer Network : JNCCN 11: 78-98.
134.

Byers, L. A., and C. M. Rudin. 2015. Small cell lung cancer: where do we
go from here? Cancer 121: 664-672.

135.

Toyooka, S., T. Tsuda, and A. F. Gazdar. 2003. The TP53 gene, tobacco
exposure, and lung cancer. Hum Mutat 21: 229-239.

136.

George, J., J. S. Lim, S. J. Jang, Y. Cun, L. Ozretic, G. Kong, F. Leenders,
X. Lu, L. Fernandez-Cuesta, G. Bosco, C. Muller, I. Dahmen, N. S.
Jahchan, K. S. Park, D. Yang, A. N. Karnezis, D. Vaka, A. Torres, M. S.
Wang, J. O. Korbel, R. Menon, S. M. Chun, D. Kim, M. Wilkerson, N.
Hayes, D. Engelmann, B. Putzer, M. Bos, S. Michels, I. Vlasic, D. Seidel,
B. Pinther, P. Schaub, C. Becker, J. Altmuller, J. Yokota, T. Kohno, R.
Iwakawa, K. Tsuta, M. Noguchi, T. Muley, H. Hoffmann, P. A. Schnabel, I.
Petersen, Y. Chen, A. Soltermann, V. Tischler, C. M. Choi, Y. H. Kim, P.
P. Massion, Y. Zou, D. Jovanovic, M. Kontic, G. M. Wright, P. A. Russell,
B. Solomon, I. Koch, M. Lindner, L. A. Muscarella, A. la Torre, J. K. Field,
M. Jakopovic, J. Knezevic, E. Castanos-Velez, L. Roz, U. Pastorino, O. T.
Brustugun, M. Lund-Iversen, E. Thunnissen, J. Kohler, M. Schuler, J.
Botling, M. Sandelin, M. Sanchez-Cespedes, H. B. Salvesen, V. Achter, U.
Lang, M. Bogus, P. M. Schneider, T. Zander, S. Ansen, M. Hallek, J. Wolf,
M. Vingron, Y. Yatabe, W. D. Travis, P. Nurnberg, C. Reinhardt, S.
Perner, L. Heukamp, R. Buttner, S. A. Haas, E. Brambilla, M. Peifer, J.

146

Sage, and R. K. Thomas. 2015. Comprehensive genomic profiles of small
cell lung cancer. Nature 524: 47-53.
137.

Rudin, C. M., S. Durinck, E. W. Stawiski, J. T. Poirier, Z. Modrusan, D. S.
Shames, E. A. Bergbower, Y. Guan, J. Shin, J. Guillory, C. S. Rivers, C.
K. Foo, D. Bhatt, J. Stinson, F. Gnad, P. M. Haverty, R. Gentleman, S.
Chaudhuri, V. Janakiraman, B. S. Jaiswal, C. Parikh, W. Yuan, Z. Zhang,
H. Koeppen, T. D. Wu, H. M. Stern, R. L. Yauch, K. E. Huffman, D. D.
Paskulin, P. B. Illei, M. Varella-Garcia, A. F. Gazdar, F. J. de Sauvage, R.
Bourgon, J. D. Minna, M. V. Brock, and S. Seshagiri. 2012.
Comprehensive genomic analysis identifies SOX2 as a frequently
amplified gene in small-cell lung cancer. Nature genetics 44: 1111-1116.

138.

Kiefer, P. E., G. Bepler, M. Kubasch, and K. Havemann. 1987.
Amplification and expression of protooncogenes in human small cell lung
cancer cell lines. Cancer research 47: 6236-6242.

139.

Krystal, G., M. Birrer, J. Way, M. Nau, E. Sausville, C. Thompson, J.
Minna, and J. Battey. 1988. Multiple mechanisms for transcriptional
regulation of the myc gene family in small-cell lung cancer. Molecular and
cellular biology 8: 3373-3381.

140.

Umemura, S., S. Mimaki, H. Makinoshima, S. Tada, G. Ishii, H. Ohmatsu,
S. Niho, K. Yoh, S. Matsumoto, A. Takahashi, M. Morise, Y. Nakamura, A.
Ochiai, K. Nagai, R. Iwakawa, T. Kohno, J. Yokota, Y. Ohe, H. Esumi, K.
Tsuchihara, and K. Goto. 2014. Therapeutic priority of the

147

PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a
comprehensive genomic analysis. J Thorac Oncol 9: 1324-1331.
141.

Ross, J. S., K. Wang, O. R. Elkadi, A. Tarasen, L. Foulke, C. E. Sheehan,
G. A. Otto, G. Palmer, R. Yelensky, D. Lipson, J. Chmielecki, S. M. Ali, J.
Elvin, D. Morosini, V. A. Miller, and P. J. Stephens. 2014. Next-generation
sequencing reveals frequent consistent genomic alterations in small cell
undifferentiated lung cancer. Journal of clinical pathology 67: 772-776.

142.

Byers, L. A., J. Wang, M. B. Nilsson, J. Fujimoto, P. Saintigny, J. Yordy, U.
Giri, M. Peyton, Y. H. Fan, L. Diao, F. Masrorpour, L. Shen, W. Liu, B.
Duchemann, P. Tumula, V. Bhardwaj, J. Welsh, S. Weber, B. S. Glisson,
N. Kalhor, Wistuba, II, L. Girard, S. M. Lippman, G. B. Mills, K. R.
Coombes, J. N. Weinstein, J. D. Minna, and J. V. Heymach. 2012.
Proteomic profiling identifies dysregulated pathways in small cell lung
cancer and novel therapeutic targets including PARP1. Cancer discovery
2: 798-811.

143.

Coe, B. P., K. L. Thu, S. Aviel-Ronen, E. A. Vucic, A. F. Gazdar, S. Lam,
M. S. Tsao, and W. L. Lam. 2013. Genomic deregulation of the E2F/Rb
pathway leads to activation of the oncogene EZH2 in small cell lung
cancer. PloS one 8: e71670.

144.

Hubaux, R., K. L. Thu, B. P. Coe, C. MacAulay, S. Lam, and W. L. Lam.
2013. EZH2 promotes E2F-driven SCLC tumorigenesis through
modulation of apoptosis and cell-cycle regulation. J Thorac Oncol 8: 11021106.

148

145.

Poirier, J. T., E. E. Gardner, N. Connis, A. L. Moreira, E. de Stanchina, C.
L. Hann, and C. M. Rudin. 2015. DNA methylation in small cell lung
cancer defines distinct disease subtypes and correlates with high
expression of EZH2. Oncogene.

146.

Murai, F., D. Koinuma, A. Shinozaki-Ushiku, M. Fukayama, K. Miyaozono,
and S. Ehata. 2015. EZH2 promotes progression of small cell lung cancer
by suppressing the TGF-β-Smad-ASCL1 pathway. Cell Discovery 1:
15026.

147.

Gardner, E. E., B. H. Lok, V. E. Schneeberger, P. Desmeules, L. A. Miles,
P. K. Arnold, A. Ni, I. Khodos, E. de Stanchina, T. Nguyen, J. Sage, J. E.
Campbell, S. Ribich, N. Rekhtman, A. Dowlati, P. P. Massion, C. M.
Rudin, and J. T. Poirier. 2017. Chemosensitive Relapse in Small Cell Lung
Cancer Proceeds through an EZH2-SLFN11 Axis. Cancer cell 31: 286299.

148.

Dooley, A. L., M. M. Winslow, D. Y. Chiang, S. Banerji, N. Stransky, T. L.
Dayton, E. L. Snyder, S. Senna, C. A. Whittaker, R. T. Bronson, D.
Crowley, J. Barretina, L. Garraway, M. Meyerson, and T. Jacks. 2011.
Nuclear factor I/B is an oncogene in small cell lung cancer. Genes &
development 25: 1470-1475.

149.

Denny, S. K., D. Yang, C. H. Chuang, J. J. Brady, J. S. Lim, B. M. Gruner,
S. H. Chiou, A. N. Schep, J. Baral, C. Hamard, M. Antoine, M. Wislez, C.
S. Kong, A. J. Connolly, K. S. Park, J. Sage, W. J. Greenleaf, and M. M.

149

Winslow. 2016. Nfib Promotes Metastasis through a Widespread Increase
in Chromatin Accessibility. Cell 166: 328-342.
150.

Semenova, E. A., M. C. Kwon, K. Monkhorst, J. Y. Song, R. Bhaskaran,
O. Krijgsman, T. Kuilman, D. Peters, W. A. Buikhuisen, E. F. Smit, C.
Pritchard, M. Cozijnsen, J. van der Vliet, J. Zevenhoven, J. P. Lambooij,
N. Proost, E. van Montfort, A. Velds, I. J. Huijbers, and A. Berns. 2016.
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer
Progression in Mice and Marks Metastatic Disease in Patients. Cell
reports 16: 631-643.

151.

Fiorentino, F. P., E. Tokgun, S. Sole-Sanchez, S. Giampaolo, O. Tokgun,
T. Jauset, T. Kohno, M. Perucho, L. Soucek, and J. Yokota. 2016. Growth
suppression by MYC inhibition in small cell lung cancer cells with TP53
and RB1 inactivation. Oncotarget.

152.

Augustyn, A., M. Borromeo, T. Wang, J. Fujimoto, C. Shao, P. D. Dospoy,
V. Lee, C. Tan, J. P. Sullivan, J. E. Larsen, L. Girard, C. Behrens,
Wistuba, II, Y. Xie, M. H. Cobb, A. F. Gazdar, J. E. Johnson, and J. D.
Minna. 2014. ASCL1 is a lineage oncogene providing therapeutic targets
for high-grade neuroendocrine lung cancers. Proceedings of the National
Academy of Sciences of the United States of America 111: 14788-14793.

153.

Christensen, C. L., N. Kwiatkowski, B. J. Abraham, J. Carretero, F. AlShahrour, T. Zhang, E. Chipumuro, G. S. Herter-Sprie, E. A. Akbay, A.
Altabef, J. Zhang, T. Shimamura, M. Capelletti, J. B. Reibel, J. D.
Cavanaugh, P. Gao, Y. Liu, S. R. Michaelsen, H. S. Poulsen, A. R. Aref,

150

D. A. Barbie, J. E. Bradner, R. E. George, N. S. Gray, R. A. Young, and K.
K. Wong. 2014. Targeting transcriptional addictions in small cell lung
cancer with a covalent CDK7 inhibitor. Cancer cell 26: 909-922.
154.

Loven, J., H. A. Hoke, C. Y. Lin, A. Lau, D. A. Orlando, C. R. Vakoc, J. E.
Bradner, T. I. Lee, and R. A. Young. 2013. Selective inhibition of tumor
oncogenes by disruption of super-enhancers. Cell 153: 320-334.

155.

Pott, S., and J. D. Lieb. 2015. What are super-enhancers? Nature
genetics 47: 8-12.

156.

Kato, F., F. P. Fiorentino, A. Alibes, M. Perucho, M. Sanchez-Cespedes,
T. Kohno, and J. Yokota. 2016. MYCL is a target of a BET bromodomain
inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer
cells. Oncotarget.

157.

Jahchan, N. S., J. S. Lim, B. Bola, K. Morris, G. Seitz, K. Q. Tran, L. Xu, F.
Trapani, C. J. Morrow, S. Cristea, G. L. Coles, D. Yang, D. Vaka, M. S.
Kareta, J. George, P. K. Mazur, T. Nguyen, W. C. Anderson, S. J. Dylla, F.
Blackhall, M. Peifer, C. Dive, and J. Sage. 2016. Identification and
Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung
Cancer. Cell reports 16: 644-656.

158.

Pleasance, E. D., P. J. Stephens, S. O'Meara, D. J. McBride, A. Meynert,
D. Jones, M. L. Lin, D. Beare, K. W. Lau, C. Greenman, I. Varela, S. NikZainal, H. R. Davies, G. R. Ordonez, L. J. Mudie, C. Latimer, S. Edkins, L.
Stebbings, L. Chen, M. Jia, C. Leroy, J. Marshall, A. Menzies, A. Butler, J.
W. Teague, J. Mangion, Y. A. Sun, S. F. McLaughlin, H. E. Peckham, E.

151

F. Tsung, G. L. Costa, C. C. Lee, J. D. Minna, A. Gazdar, E. Birney, M. D.
Rhodes, K. J. McKernan, M. R. Stratton, P. A. Futreal, and P. J. Campbell.
2010. A small-cell lung cancer genome with complex signatures of
tobacco exposure. Nature 463: 184-190.
159.

Teves, S. S., L. An, A. S. Hansen, L. Xie, X. Darzacq, and R. Tjian. 2016.
A dynamic mode of mitotic bookmarking by transcription factors. eLife 5.

160.

Li, Y., H. Wen, Y. Xi, K. Tanaka, H. Wang, D. Peng, Y. Ren, Q. Jin, S. Y.
Dent, W. Li, H. Li, and X. Shi. 2014. AF9 YEATS domain links histone
acetylation to DOT1L-mediated H3K79 methylation. Cell 159: 558-571.

161.

Wan, L., H. Wen, Y. Li, J. Lyu, Y. Xi, T. Hoshii, J. K. Joseph, X. Wang, Y.
E. Loh, M. A. Erb, A. L. Souza, J. E. Bradner, L. Shen, W. Li, H. Li, C. D.
Allis, S. A. Armstrong, and X. Shi. 2017. ENL links histone acetylation to
oncogenic gene expression in acute myeloid leukaemia. Nature 543: 265269.

162.

Egan, B., C. C. Yuan, M. L. Craske, P. Labhart, G. D. Guler, D. Arnott, T.
M. Maile, J. Busby, C. Henry, T. K. Kelly, C. A. Tindell, S. Jhunjhunwala,
F. Zhao, C. Hatton, B. M. Bryant, M. Classon, and P. Trojer. 2016. An
Alternative Approach to ChIP-Seq Normalization Enables Detection of
Genome-Wide Changes in Histone H3 Lysine 27 Trimethylation upon
EZH2 Inhibition. PloS one 11: e0166438.

163.

Torres, I. O., K. M. Kuchenbecker, C. I. Nnadi, R. J. Fletterick, M. J. Kelly,
and D. G. Fujimori. 2015. Histone demethylase KDM5A is regulated by its

152

reader domain through a positive-feedback mechanism. Nat Commun 6:
6204.
164.

Lan, F., R. E. Collins, R. De Cegli, R. Alpatov, J. R. Horton, X. Shi, O.
Gozani, X. Cheng, and Y. Shi. 2007. Recognition of unmethylated histone
H3 lysine 4 links BHC80 to LSD1-mediated gene repression. Nature 448:
718-722.

165.

Manning, E. T., T. Ikehara, T. Ito, J. T. Kadonaga, and W. L. Kraus. 2001.
p300 forms a stable, template-committed complex with chromatin: role for
the bromodomain. Molecular and cellular biology 21: 3876-3887.

166.

Hilton, I. B., A. M. D'Ippolito, C. M. Vockley, P. I. Thakore, G. E. Crawford,
T. E. Reddy, and C. A. Gersbach. 2015. Epigenome editing by a CRISPRCas9-based acetyltransferase activates genes from promoters and
enhancers. Nature biotechnology 33: 510-517.

167.

Rada-Iglesias, A., R. Bajpai, T. Swigut, S. A. Brugmann, R. A. Flynn, and
J. Wysocka. 2011. A unique chromatin signature uncovers early
developmental enhancers in humans. Nature 470: 279-283.

168.

Buecker, C., and J. Wysocka. 2012. Enhancers as information integration
hubs in development: lessons from genomics. Trends in genetics : TIG 28:
276-284.

169.

Zentner, G. E., P. J. Tesar, and P. C. Scacheri. 2011. Epigenetic
signatures distinguish multiple classes of enhancers with distinct cellular
functions. Genome research 21: 1273-1283.

153

170.

Musselman, C. A., M. E. Lalonde, J. Cote, and T. G. Kutateladze. 2012.
Perceiving the epigenetic landscape through histone readers. Nature
structural & molecular biology 19: 1218-1227.

171.

Andrews, F. H., B. D. Strahl, and T. G. Kutateladze. 2016. Insights into
newly discovered marks and readers of epigenetic information. Nature
chemical biology 12: 662-668.

172.

Taverna, S. D., H. Li, A. J. Ruthenburg, C. D. Allis, and D. J. Patel. 2007.
How chromatin-binding modules interpret histone modifications: lessons
from professional pocket pickers. Nature structural & molecular biology 14:
1025-1040.

173.

An, W., and R. G. Roeder. 2003. Direct association of p300 with
unmodified H3 and H4 N termini modulates p300-dependent acetylation
and transcription of nucleosomal templates. The Journal of biological
chemistry 278: 1504-1510.

174.

Augert, A., and D. MacPherson. 2014. Treating transcriptional addiction in
small cell lung cancer. Cancer cell 26: 783-784.

175.

Jahchan, N. S., J. T. Dudley, P. K. Mazur, N. Flores, D. Yang, A.
Palmerton, A. F. Zmoos, D. Vaka, K. Q. Tran, M. Zhou, K. Krasinska, J.
W. Riess, J. W. Neal, P. Khatri, K. S. Park, A. J. Butte, and J. Sage. 2013.
A drug repositioning approach identifies tricyclic antidepressants as
inhibitors of small cell lung cancer and other neuroendocrine tumors.
Cancer discovery 3: 1364-1377.

154

176.

Schaffer, B. E., K. S. Park, G. Yiu, J. F. Conklin, C. Lin, D. L. Burkhart, A.
N. Karnezis, E. A. Sweet-Cordero, and J. Sage. 2010. Loss of p130
accelerates tumor development in a mouse model for human small-cell
lung carcinoma. Cancer research 70: 3877-3883.

177.

Kim, D. W., N. Wu, Y. C. Kim, P. F. Cheng, R. Basom, D. Kim, C. T. Dunn,
A. Y. Lee, K. Kim, C. S. Lee, A. Singh, A. F. Gazdar, C. R. Harris, R. N.
Eisenman, K. S. Park, and D. MacPherson. 2016. Genetic requirement for
Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell
lung cancer. Genes & development 30: 1289-1299.

178.

Zhang, W., L. Girard, Y. A. Zhang, T. Haruki, M. Papari-Zareei, V. Stastny,
H. K. Ghayee, K. Pacak, T. G. Oliver, J. D. Minna, and A. F. Gazdar.
2018. Small cell lung cancer tumors and preclinical models display
heterogeneity of neuroendocrine phenotypes. Transl Lung Cancer Res 7:
32-49.

179.

Borromeo, M. D., T. K. Savage, R. K. Kollipara, M. He, A. Augustyn, J. K.
Osborne, L. Girard, J. D. Minna, A. F. Gazdar, M. H. Cobb, and J. E.
Johnson. 2016. ASCL1 and NEUROD1 Reveal Heterogeneity in
Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic
Programs. Cell reports 16: 1259-1272.

180.

Mollaoglu, G., M. R. Guthrie, S. Bohm, J. Bragelmann, I. Can, P. M.
Ballieu, A. Marx, J. George, C. Heinen, M. D. Chalishazar, H. Cheng, A. S.
Ireland, K. E. Denning, A. Mukhopadhyay, J. M. Vahrenkamp, K. C.
Berrett, T. L. Mosbruger, J. Wang, J. L. Kohan, M. E. Salama, B. L. Witt,

155

M. Peifer, R. K. Thomas, J. Gertz, J. E. Johnson, A. F. Gazdar, R. J.
Wechsler-Reya, M. L. Sos, and T. G. Oliver. 2016. MYC Drives
Progression of Small Cell Lung Cancer to a Variant Neuroendocrine
Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer cell.
181.

Kaur, G., R. A. Reinhart, A. Monks, D. Evans, J. Morris, E. Polley, and B.
A. Teicher. 2016. Bromodomain and hedgehog pathway targets in small
cell lung cancer. Cancer Lett 371: 225-239.

182.

van Meerbeeck, J. P., D. A. Fennell, and D. K. De Ruysscher. 2011.
Small-cell lung cancer. Lancet 378: 1741-1755.

183.

Kim, D. W., K. C. Kim, K. B. Kim, C. T. Dunn, and K. S. Park. 2018.
Transcriptional deregulation underlying the pathogenesis of small cell lung
cancer. Transl Lung Cancer Res 7: 4-20.

184.

Jia, D., A. Augert, D. W. Kim, E. Eastwood, N. Wu, A. H. Ibrahim, K. B.
Kim, C. T. Dunn, S. P. S. Pillai, A. F. Gazdar, H. Bolouri, K. S. Park, and
D. MacPherson. 2018. Crebbp Loss Drives Small Cell Lung Cancer and
Increases Sensitivity to HDAC Inhibition. Cancer discovery 8: 1422-1437.

185.

Ramos, Y. F., M. S. Hestand, M. Verlaan, E. Krabbendam, Y. Ariyurek, M.
van Galen, H. van Dam, G. J. van Ommen, J. T. den Dunnen, A.
Zantema, and P. A. t Hoen. 2010. Genome-wide assessment of
differential roles for p300 and CBP in transcription regulation. Nucleic
acids research 38: 5396-5408.

186.

Tate, J. G., S. Bamford, H. C. Jubb, Z. Sondka, D. M. Beare, N. Bindal, H.
Boutselakis, C. G. Cole, C. Creatore, E. Dawson, P. Fish, B. Harsha, C.

156

Hathaway, S. C. Jupe, C. Y. Kok, K. Noble, L. Ponting, C. C. Ramshaw,
C. E. Rye, H. E. Speedy, R. Stefancsik, S. L. Thompson, S. Wang, S.
Ward, P. J. Campbell, and S. A. Forbes. 2018. COSMIC: the Catalogue Of
Somatic Mutations In Cancer. Nucleic acids research.
187.

Zhou, X., M. N. Edmonson, M. R. Wilkinson, A. Patel, G. Wu, Y. Liu, Y. Li,
Z. Zhang, M. C. Rusch, M. Parker, J. Becksfort, J. R. Downing, and J.
Zhang. 2016. Exploring genomic alteration in pediatric cancer using
ProteinPaint. Nature genetics 48: 4-6.

157

Vita

Yongming Xue was born in Jinan, China on July 16, 1988, the son of Ying Xu
and Bin Xue. After completing his education at Shandong Experimental High
School, Jinan, China in 2007, he entered China Agricultural University (CAU) in
Beijing, China. He received the degree of Bachelor of Sciences with a major in
biological sciences from CAU in July 2011. For the next three years, he worked
as a graduate research assistant and lab technician in Chinese Academy of
Sciences in Beijing, China. In August of 2014 he entered The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical
Sciences.

Permanent address:
5731 Gulfton Street, APT 2704,
Houston, Texas 77030

158

